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Abstract
Nocardiosis is caused by opportunistic, soil-borne bacteria in the genus Nocardia. The
disease is characterized by severe pulmonary and systemic infections, and mild to severe skin
infections. People thought to be at risk are older adults and those with underlying
comorbidities, particularly immunosuppressive conditions. Treatment duration can be long and
may require antimicrobial and surgical interventions. Considered a rare disease, the existing
literature and knowledge base regarding the clinical presentation, persons at risk, incidence,
and mortality estimates are primarily from case series or limited hospital-based retrospective
analyses. Evaluating the disease characteristics from more generalizable data can aid in our
understanding of the disease and may aid in identifying persons who may be at greater risk of
death.
The purpose of this dissertation is to use population-level administrative data to
develop generalizable estimates of the incidence and mortality, and to evaluate risk factors,
including identifying a predictive comorbidity measure. The 100% Medicare Fee-For-Service
data, and the Healthcare Utilization Project’s State Inpatient Databases and State Ambulatory
and Surgery and Services Databases were used to evaluate nocardiosis among Medicare
beneficiaries as well as all payer hospitalization and visit discharges. The demographics, costs,
visits, and risk factors are described from each data source, and incidence and hospitalization
rates are calculated. Comorbidity measures are evaluated for prediction of mortality. Time to
death and covariates associated with mortality are calculated from the person-based
longitudinal Medicare data and the HCUP hospital visit-based data, respectively.
The findings of this dissertation describe nocardiosis that can be generalized to all Feefor-Service Medicare beneficiaries and almost half the US population. Nocardiosis cases and
nocardiosis-associated visits were more often male, older, and sicker than the general Medicare
and US populations. Mortality was associated with disseminated nocardiosis, cerebrovascular
disease, and the presence of additional comorbid conditions, when controlling for other factors.
Additional findings will be discussed.
These findings can provide additional insight into persons who may be at greater risk of
developing nocardiosis and can provide clinicians with factors that are associated with
mortality. These findings provide a baseline from which future population-level analyses can be
compared.
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Chapter 1: Literature Review and Statement of
Purpose
I. Overview
Population-based descriptions of the disease nocardiosis and its etiologic agent, the
bacterial genus Nocardia, in the United States are scarce despite a substantial body of research
(1-3). Nocardiosis is a medically important disease that more frequently affects
immunocompromised patients (4, 5). There are varied clinical presentations that can make
clinical recognition challenging (6), and as a soil-borne pathogen, prevention methods are
limited (4). The disease is difficult to treat, requiring months or years of antimicrobial therapy
(7), and contributes to mortality in patients with underlying conditions (8).
There are several reasons for the lack of population-level and generalizable data. First,
nocardiosis is challenging to study because it is relatively rare (6), thus selecting a generalizable
and nationally representative sample has been difficult. Medical discharge data could not be
used because nocardiosis was combined with other bacterial and fungal agents in medical
coding versions prior to 2015 (9). Meanwhile, facility-based studies lack generalizability due to
social and geographic variations (3), and reports from facilities that target patient populations
with known nocardiosis risk factors, such as transplant (10-12) or cancer hospitals (13, 14), are
not generalizable to a wider population.
Additionally, available diagnostic methods can limit the ability to diagnose the disease
accurately and rapidly (15). Many disparate laboratories in the United States perform reference
testing of Nocardia spp., which produce non-representative reports of isolate identifications (2,
16, 17). Analysis of Nocardia by species is also limited, and due to major taxonomic changes
over time (15), retrospective analyses of Nocardia species may need to be retested using
modern molecular methods because of historical misidentification and misclassification (15,
18).
Due to the ageing United States population (19) and increasing prevalence of
immunocompromising conditions among American adults (20), it is important to describe
nocardiosis using generalizable population–level data. These descriptions may further improve
10

clinical recognition of nocardiosis, push clinicians to request species-level identification for
improved treatment, rapid provision of appropriate antimicrobials, and provide a nationally
representative description of nocardiosis for the United States.

II. Literature review
Microbiology
Nocardia is a genus in the class Actinobacteria and order Actinomycetales (6). The genus
is composed of gram-positive, partly acid-fast bacilli with filamentous and branching growth;
they tend to be slow growers and produce aerial mycelia (6, 14, 21). The taxonomy has evolved
since the organism was first identified by Nocard in 1888 and first named by Trevisan a year
later (22). Historically, morphologic and phenotypic characteristics were used to define species
(15); however, these methods do not have the granularity to adequately differentiate species
within the genus (15, 18). These limitations and other conflicts have to led to the incorrect
identification of bacteria from other genera as Nocardia, and inaccurate classification within
Nocardia species (15).
Nocardia asteroides was noted to have heterogeneity within the species (23). It was
later termed a “complex” (15) that was separated into seven groups of species (1-6, and
miscellaneous) based on antimicrobial susceptibility patterns to various classes of
antimicrobials (24). These susceptibility patterns were used to determine the antimicrobial
treatment regimen to maximize outcomes, because of varied antimicrobial resistance by group
(24, 25).
Molecular diagnostic methods have since distinguished the Nocardia asteroides complex
into several separate species, including the pathogenic species N. abscessus (previously group
1), N. nova (within a complex of species, group 3), N. cyriacigeorgica (group 4), and N. farcinica
(group 5) (25). As a result, N. asteroides complex is no longer an approved name (26), and more
than 80 species are now identified, of which 49 have been isolated as human pathogens (15,
25). Improved methodologies shorten diagnosis delays (15), increase the recognition of the
etiologic agent (14), and enable accurate antimicrobial susceptibility testing (17).
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Geographic distribution and ecology
A few studies have attempted to evaluate the geographic distribution of Nocardia
species, primarily using clinical isolates (3, 27, 28). The genus Nocardia appears to be ubiquitous
in many locations around the world (2, 27, 29-37). Yet, understanding the distribution in the
United States is limited by reporting and submission bias. In a review of 765 specimens
submitted to CDC over 10 years, 44 states submitted specimens, of which 18% were submitted
by Alabama and 10% from Florida (2). A study from Utah over five years reported 2,198
specimens submitted from 40 states with no further geographic specification (17).
There may be geographic variation by infecting species. The previously named N.
asteroides, which has been separated into multiple diverse species (26), and N. farcinica have
been reported to have an even distribution across the United States (6, 38). One report claims
that N. nova is less frequently identified in the southwest (38). Of N. brasiliensis case reports in
the United States up to 1984, 63% were published in five states (Texas, California, Florida,
North Carolina, and Oklahoma) (3), although these results are perhaps limited by publication
bias. Another author based in the southwestern U.S. has stated that N. brasiliensis is most
common in the southeast (based on the previously mentioned study) and the southwest, based
on receipt of 40 N. brasiliensis isolates out of 455 Nocardia isolates in five years (38). Uhde et al
report that 59 of 106 (56%) of N. brasiliensis isolates originated from Tennessee and Florida
over a 10 year period (2), which supports the claim of a higher prevalence in the southeast.
Ecological characteristics likely influence the presence of Nocardia spp. organisms and
geographic variation of Nocardia spp. in the soil. It is generally accepted that nocardiosis is
endemic in tropical and subtropical climates, while infections are less frequent in temperate
climates (6). Warmth and humidity have been associated with nocardial keratitis (39) and
actinomycetoma (40). This association may be intensified by greater soil exposure due to the
types of clothing and shoes worn (or not worn) in hot and humid environments (35, 39, 40).
These results contradict a statement of a regionally-based author that most U.S. cases occur in
the hot, dry, and windy climate of the American southwest (38).
Nocardia species diversity, but not the presence of Nocardia spp., may be influenced by
soil characteristics. A soil study from Iran found that 60% of “N. asteroides complex” were
12

found in soil with pH 7.1-8.0, and 63.6% of N. brasiliensis isolates were from soil pH 8.01-9 (41).
The greatest frequency of “N. asteroides complex” were recovered from a desert climate (41),
contrary to associations of nocardiosis with humidity (39, 40). Despite the findings that soil
characteristic preferences may differ by Nocardia species, this was not borne out in a study of
human infections at a local level (28). The evaluation did not find evidence of an association of
soil characteristics at case residences or geospatial clustering of case residences regardless of
infecting species (28). Host susceptibility and marginal ecological variation at the local level may
affect the influence of species soil preference.
In summary, a study evaluating Nocardia spp. in the soil in the United States would be
beneficial to understand the distribution and species diversity. A population-based analysis of
disease prevalence may guide such a study.

Clinical manifestations
There are three main forms of disease due to Nocardia: primary cutaneous, pulmonary,
and disseminated infections (6). Less frequent sources or presentations of disease include
bacteremia, ocular, and other extra-pulmonary infections (6); other authors describe additional
forms of disease: extrapulmonary, central nervous system (CNS), and mycetoma (42). The most
common forms will be described below, as well as a few forms of extrapulmonary disease.

Cutaneous
Primary cutaneous nocardiosis is caused by the direct inoculation with soil
contaminated with Nocardia spp. (3, 4, 43). Some cases report no trauma, such as innocuous
events including direct contact of open cuts with soil when gardening (3, 43) or a thorn prick
(44). Traumatic inoculation has been reported, such as injuries from a car accident (45) and
through nosocomial exposure (46). Nocardia brasiliensis may account for up to 80% of
cutaneous infections (6, 42). Interestingly, one study in Houston found N. farcinica to most
commonly cause skin infections, although this was in a severely immunocompromised
population (14).
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Primary cutaneous infection can disseminate hematogenously to cause systemic, or
disseminated, nocardiosis (47). Primary cutaneous infections can present as superficial,
lymphocutaneous, subcutaneous/ actinomycetoma (48). Meanwhile, it is estimated that 8-10%
of cutaneous infections are secondary to a primary pulmonary infection that disseminated to
the skin (42, 48).
The least severe form, patients with superficial skin infections may have ulcers (49),
cellulitis (50), abscesses (51), granulomas (52), as well as pustules, plaques, or papules (53). The
superficial form was found to be the most common form of cutaneous nocardiosis in the United
States in one literature review of 75 cases (53). The authors also found an average time to
diagnosis of 12.7 weeks (range:0.5-52) from 43 patients with superficial cutaneous nocardiosis,
and only 32.6% were immunocompromised (53). Only infrequently do superficial infections
progress into disseminated infections (54). Differential diagnoses include other pyogenic
bacterial infections, including Staphylococci and group A streptococci (3, 43), sporotrichosis (6,
47), tularemia (7, 47), or Erysipelothrix spp. infections (7).
An estimated 1/3 of cutaneous infections progress to the lymphocutaneous form (55),
which involves the lymphatic system; it is also called sporotrichoid nocardiosis because of its
similarity to sporotrichosis (16). In one series, patients frequently presented with a nodule, as
well as local pain, edema, erythema, warmth, and induration (43). Some patients presented
with lymphangitis and lymphadenopathy (43), as well as cellulitis; the lesions may progress to
subcutaneous abscesses (47, 53). Average time to diagnosis of 26 patients was 20.6 weeks
(range 0.5-208) (53), slightly longer than that for superficial infections; 46.2% were
immunocompromised (53). Differential diagnoses include sporotrichosis (16) and
Mycobacterium marinum infection (7, 56).
Both forms often present on the extremities (14, 43, 47, 53), which may point to the
ability for trauma to occur on uncovered skin. Specimens for diagnosis include fluid drained
from abscesses or lesions for culture, or biopsies of the lesions to identify histopathologic
evidence of Nocardia spp. bacilli (43, 47, 53). Co-infections may confuse the diagnosis (3, 56),
and contamination of the wound with multiple organisms can outcompete or conflate the
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causative agent of the infection (3). Finally, a full examination must be done to rule out
secondary cutaneous infection due to dissemination (4).

Actinomycetoma
Bacterial subcutaneous infections are called actinomycetomas, although they are often
referred to collectively as mycetoma due to variable bacterial and fungal etiologies; the fungal
form is known as eumycetoma (57). The World Health Assembly agreed to add mycetoma as a
neglected tropical disease in 2016 (WHA69.21). Nocardia brasiliensis is reportedly the most
frequent nocardial etiology of bacterial mycetoma (3, 4). Actinomycetoma occurs
predominately in tropical areas and is associated with humid and hot climates (35, 40),
although the global distribution of actinomycetoma and eumycetoma appears to vary. Mexico
reports a majority of mycetoma due to actinomycetes (58), while a majority of mycetomas in
Sudan are fungal infections (59). Rarely reported in the United States, cases have primarily
occurred in states bordering Mexico (53). Mycetomas are likely due to small traumatic
inoculations on the feet or lower legs from walking barefoot or in open-toed shoes (35, 40).
Actinomycetomas are often chronic infections that progress to cause severe morbidity,
particularly through deep tissue necrosis, bone damage, and subsequent disability (35, 40, 53).
The disease most often appears as tumor-like growths, abscesses, and indolent nodules with
draining sinuses predominately affecting the lower legs or feet (35, 40). Differential diagnoses
include fungal infections (e.g., eumycetoma) and actinomycosis (7). Specimens for diagnosis
include grains exuded from the mycetoma, either superficially collected from the draining
sinuses for microscopy, or by deep biopsy for histopathology or culture (60). The color and
other morphological characteristics of the grain are used to help differentiate the etiologic
agent, which may allow for appropriate antimicrobial or antifungal treatment (60). Grain
examination does not provide a definitive diagnosis (61);however, diagnosis is likely made at
field clinics in rural areas, which relies upon clinical diagnosis in the absence of culture, PCR,
pathology, or access to a referral center (62). Clinical diagnosis may not differentiate between
fungal and bacterial infection, and the inappropriate treatment only delays treatment further
and exacerbates morbidity (62).
15

Pulmonary
Primary pulmonary nocardiosis is thought to be caused from inhalation of aerosolized
spores or mycelia (4). Pulmonary infection is the most common form of disease in the United
States (6, 48), and more often affects patients with structural lung disease (28, 63),
immunocompromising conditions (6), or those taking corticosteroids for more than six months
(28, 63).
Respiratory-tract colonization is reported in many reviews of pulmonary infections (6467). Some lung diseases, such as cystic fibrosis, may predispose patients to respiratory tract
colonization (67). Georghiou et al found 20% of Nocardia spp. isolates were not associated with
clinical symptoms and the patients were assumed to be colonized (55), while Fujita et al found
40% of immunocompetent patients were colonized (64). If a patient has symptoms or signs of
lung infection and a positive Nocardia spp. culture from a respiratory specimen, the result
should be assumed to be clinically important (64, 66).
The disease is characterized by an acute onset with inflammatory response, which
progresses to granulomatous inflammation and necrotic abscess development (38, 68).
Symptoms are usually nonspecific, including cough, dyspnea, and fever (14, 64, 65, 68, 69);
pleuritic chest pain has also been reported (69). One study found that symptoms did not differ
significantly by immune status (64).
Clinical signs include presence of leukocytosis and elevated C-reactive protein (14, 64,
68). Frequent radiographic findings include the presence of one or more lung nodules, lobar
consolidation, and pleural effusion (14, 64, 65, 68); pulmonary infiltrates and necrotizing
granulomas may be present (14) and lung findings are frequently bilateral (8). Cavitation is
reported more frequently among immunocompromised patients (5, 64).
Time from onset to diagnosis varies widely. An older literature review found the average
time to diagnosis was 11.7 weeks (SD: 16.5, range 2 days-29 months) while a more recent study
found an average of 42 days (SD: 40) (33). Although reasons for the delays were not explained,
more rapid diagnostic results and improved clinical recognition may be factors in the
differences between periods. When differentiated by immune status, mean delay was 45.8 days
16

(SD: 45) for immunocompetent patients who presented with subacute infections, and 7.4 days
(SD: 12) for immunosuppressed patients with acute infections (64). Delays in diagnosis (70) and
acute disease (68) are associated with poor outcomes and higher mortality.
The proportion of patients that progress to disseminated infection also varies and is
associated with immune status. Dissemination to an extrapulmonary site has been reported in
0-4% of immunocompetent patients and 22-28% of immunosuppressed (28, 64). When immune
status is not differentiated, the proportion ranges from 8.5%-38% (14, 69, 71).
Symptoms, signs, and radiographic findings are not sufficient for diagnosis of nocardiosis
due to their lack of specificity. Differential diagnoses for pulmonary nocardiosis include
tuberculosis and non-tuberculosis Mycobacterium infections, various fungal (e.g., Aspergillus
spp.) and bacterial infections (e.g., Rhodococcus equi in HIV-positive patients), and malignancy
(4, 7, 72).
Early specimen collection, particularly prior to antimicrobial therapy, will improve the
ability to recover organism for microbiological or histopathological diagnosis (63). Non-invasive
collection methods for respiratory specimens produces good recovery of organism (14, 33);
sputum and bronchoalveolar lavage are the most common specimens reported (14, 33, 63-65).

Disseminated
Disseminated, or systemic, infection is due to the hematogenous spread of the infection
to a non-contiguous organ or system (6, 42). It can result from primary cutaneous or pulmonary
infection; it can cause infection anywhere in the body, but predominately affects the skin,
lungs, and central nervous system (CNS) (5, 42). Other relatively common locations of
disseminated infection include the kidney (73), joints (74), retina (75), and heart (76).
Dissemination appears to occur more commonly in those with immunosuppression (5,
64). A study of four medical centers in Taiwan found only 6% of nocardiosis cases had
dissemination (77), and a surveillance study in Spain found 13.5% had disseminated disease
(34). When separated by immune status, dissemination was 0-9% among immunocompetent
and 22-27% among immunocompromised patients (5, 64). Transplant recipients are at greatest
risk of dissemination (5); 42.7% of patients experienced disseminated disease in a large multi17

site study (8). Radiological imaging is important to locate abscesses using computed
tomography (CT) or magnetic resonance imaging (MRI) (31).

CNS
In a study of 1,050 cases, 22.7% of cases (n=238) had CNS infections, of which 42% were
immunocompetent (42). Meanwhile, 44% of disseminated infections had CNS involvement (42).
Similarly, 25.6% of transplant recipients had CNS involvement (8). An estimated 38% of all CNS
nocardiosis infections are primary infections rather than disseminated infections (42).
Symptoms and signs of CNS infection may include fever, headaches, meningismus (78),
seizures (5, 78), and neurologic deficits (5, 8). However, the absence of signs does not exclude
CNS involvement; 43.3% of transplant recipients had no neurological signs or symptoms despite
presence of CNS infection on imaging (8). Thus, radiological imaging (e.g., CT, MRI) and
collection of cerebrospinal fluid is important for any patient with suspect nocardiosis,
particularly immunocompromised patients (14, 78). In this population, disease progression may
be rapid (42); the abscesses can spread by extending Nocardia spp. filaments (42). However,
progression and onset of neurologic signs can take years in immunocompetent patients (79).
Differential diagnoses may include malignancies (7, 78), vascular infarction, or other bacterial or
fungal infections (7).

Extrapulmonary disease
Other extrapulmonary forms are reported in the literature, which occur either via
dissemination from primary cutaneous or pulmonary infection, or direct inoculation (71).
Ocular
The eye can be affected with either a primary or disseminated infection (42). Corneal
lesions or keratitis can result from traumatic inoculation of the eye, eye surgery, steroid use
(80), or contamination of contact lenses (80, 81). Retinal involvement is more often associated
with disseminated disease (42). Corticosteroids are frequently used as a treatment for bacterial
keratitis and corneal ulcers, but may actually produce worse outcomes for nocardial infections
(36).
18

Osteomyelitis and septic arthritis
Nocardial osteomyelitis has been recognized as an unusual presentation since 1963,
with the first culture-proven infection of the vertebral column (82). Osteomyelitis has since
been described in the vertebra and appendicular skeleton, and are predominately disseminated
from a primary infection site (82-84). Most primary osteomyelitis cases are described in
immunocompetent individuals following traumatic inoculation (51, 85-87), although two cases
have been reported in patients with HIV (88, 89).
Septic arthritis infected with Nocardia sp. has been reported infrequently, although the
first case was reported in the English literature in 1954 (90). Infections predominately affect the
knee, and are described shortly following total knee replacement (91, 92) or periprosthetic
infection of the knee (93, 94). Two reports have described nocardial septic arthritis of the knee
joint following surgical repair of the anterior cruciate ligament in immunocompetent patients
(95, 96).

Treatment
There are no standard recommendations for nocardiosis treatment. Treatment selection
and duration must be customized to the patient based on the form and severity of disease
underlying conditions, and antimicrobial sensitivity testing (6, 7).

a) Antimicrobials
Antimicrobial susceptibility varies by Nocardia species, which were historically divided
into groups based on their susceptibility patterns to various antimicrobial classes (25, 26, 97). In
vitro and in vivo antimicrobial susceptibilities can be inconsistent (6, 7), and the organism can
be fastidious and outgrown by the presence of co-infecting bacteria (48). These factors can
make treatment selection challenging. Additionally, there has been some dispute regarding
resistance of trimethoprim sulfamethoxazole (TMP-SMX) (2, 16, 98), which is a first line and
widely used treatment for nocardiosis (7, 99). A large multi-center study from six laboratories in
the U.S. did not find evidence of substantial resistance to TMP-SMX (16).
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Often only reference laboratories will perform susceptibility testing, which can further
delay appropriate treatment (98). However, if susceptibility testing is not available, the group
antimicrobial susceptibility profiles could be used as a rough gauge to determine treatment
regimens (15, 25), although some of the groups have inconsistent patterns for some drug
classes (6, 25). Combination therapy is recommended while awaiting susceptibility results,
usually consisting of TMP-SMX and another antimicrobial agent (25). If CNS involvement is
suspected, an agent that is effective for CNS infections is preferred, such as ceftriaxone or TMPSMX (7, 25). Once the susceptibility results are known, monotherapy may be sufficient
depending on the disease severity; however, patients should be monitored for drug intolerance
(25).
Extended duration of treatment is recommended to prevent relapse from this
intracellular bacterium (7). Immunocompetent patients with uncomplicated infections are
recommended to receive at least six months of antimicrobial treatment (7, 99), although one
study found an average treatment duration among patients with superficial cutaneous
infections of four months (range 1-12 months) (53). Immunocompromised patients or those
with complicated or disseminated disease should receive 12 months or more of antimicrobial
treatment (7, 99). A suggestion for patients with CNS involvement is to treat with intravenous
antimicrobials for six weeks or more, with an additional year or more of oral antimicrobial
treatment (100).

Adjunctive care
Antimicrobials alone may be insufficient for many patients. Surgical excision, incision
and drainage, or debridement may be required for cutaneous lesions (3, 43, 47, 101), which
may be performed serially (43, 101). Skin grafts may also be needed for wound closure,
particularly for necrotic lesions (3, 101). Additionally, amputation may be performed to remove
appendages severely affected with actinomycetoma (3, 102). When a prosthetic joint is
involved, revision or one-stage replacement of the joint have been performed to remove
infected tissue and repair the prosthetic (93, 94).
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Diagnostics and antimicrobial susceptibility testing
Nocardia spp. can have fastidious growth (4), may be overgrown by other infecting
organisms (48), and clinicians may not consider an infectious etiology given similarity to some
malignancies (5, 103). Culture-based diagnostic methods are slow and phenotypic tests lack
specificity to differentiate species (15), both delay diagnosis and proper treatment. Correct
identification to the species level enables a more accurate antimicrobial treatment regimen
(25); susceptibility breakpoints have been established by the Clinical and Laboratory Standards
Institute (104).
Advanced methods can be applied to isolates to more rapidly and accurately identify the
species, and include gene sequencing (i.e., 16S) and matrix-assisted laser desorption ionization–
time of flight mass spectrometry (15). Unfortunately, more advanced identification and
susceptibility-testing methods are not frequently available at clinical laboratories (15, 98, 105).
Submission to reference laboratories delays diagnosis (15).Molecular diagnostic advancements
have improved the ability and timeliness to properly identify organisms (106-108), which can
ensure that patients receive appropriate treatment more quickly (17). Such advancements have
also most likely increased the quantity of recognized infections (98, 99), which may factor into
reports of increasing incidence (14).

Epidemiology
i.

Demographics

Many studies report that males outnumber females at a ratio of 2-3:1 (3, 65, 109-111),
but other studies show a more equitable distribution with slightly fewer females (5, 13, 21,
112). The differences in distribution may be associated with an underlying association of sex
with the risk factor of interest in the study. Two studies among solid organ transplant recipients
reported a ratio of 1.7:1 (8) and 2:1 (109) males to females, but the latter study reported a ratio
of 3:2 among all transplant patients at their facility (109). Other transplant (10, 11, 113) and
older HIV studies (32, 111, 114) report a disparate ratio by sex. Malignancy studies reported
ratios of 1:1 (13, 112) and 1.6:1 (14), non-specialty facilities reported ratios of 1.1:1 (66) - 1.3:1
(5), while national reference laboratory reports vary widely (1.4:1 (21)– 2.4:1 (115)).
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All this is to say, there is a wide distribution by sex. Of 1,959 isolates submitted to the
Centers for Disease Control and Prevention’s (CDC) Special Bacteriology Reference Laboratory
(SBRL) between 2008 and 2018, that were positive for Nocardia spp., and had information
about patient sex, 1,119 (57.1%) were from males and 840 (42.9%) were from females for a
ratio of 1.3:1 (unpublished CDC data).
McNeil et al, in the seminal summary of medically important actinomycetes, stated that
cases typically are in their “third to fourth decade” (4), although some recent studies have
average ages in the 50’s (5, 34) and 60’s (21). Reports range widely in average age reported,
which also may have an association with risk factors. The average age among patients for whom
isolates were sent to CDC between 2008 and 2018 with age information (n=1,894) was 58.0
(Standard deviation [SD]: 21.5, range 7 weeks-104) (unpublished CDC data).

Sources of disease
As saprophytic bacteria, Nocardia spp. decompose organic matter in the soil (116) and
have been found widely in soil and water (117). Generally, pulmonary exposure occurs when
aerosolized spores or mycelia are inhaled (4); the bacteria are frequently found in dust and
bioaerosols (37, 117-119). Primary pulmonary infection more often occurs in
immunocompromised individuals (6) or those with structural lung disease (28, 63).
The second exposure route is direct inoculation into the body, which is the source of
most primary cutaneous infections (3, 43, 53). Inoculation can be traumatic, such as an injury
sustained during a car accident (45) or mildly traumatic as a prick from a bush (44), through a
nosocomial exposure (46, 95, 96, 118, 120), or through dust or dirt entering into open wounds
(3, 43). In an extreme case, a patient developed nocardial meningitis following a traumatic skull
fracture (121).

Nosocomial
As previously stated, nosocomial exposures are infrequently reported in the literature;
source confirmation varies (118, 122). Exmelin et al reported an outbreak among three
immunocompromised heart transplant patients in the same ward with highly similar strains; no
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potential source was identified (46). Two instances of disseminated disease occurred in
immunocompetent cases following insertion of prostheses (120, 123), but again, the source
was not identified.
Houang et al reported the source of a nocardiosis outbreak in a renal unit was
contaminated air ducts, as they were able to recover a small number of Nocardia spp. colonies
from air, dust, and settle plates placed in the ward (118). Because molecular typing was not yet
available to confirm the relationship of the isolates, there is not confirmatory evidence of the
source of the infections. A more recent investigation used molecular typing methods to
determine that the source of an outbreak among five open heart surgery patients was an
anesthesiologist present at each surgery (124).
One study suggested that exposure to medical equipment was a possible source of
infection (125). There was extensive Nocardia spp. biofilm formation found on central venous
catheters used at a cancer facility where 10 patients had central line-associated blood stream
Nocardia spp. infections and another seven were bacteremic (125). The authors did not assert
that the infections were definitively from the catheters, although they recommended
antimicrobial treatment of central venous catheters to reduce biofilm growth. Beyond such
prophylaxis, no specific precautions are recommended to prevent Nocardia spp. nosocomial
transmission due to its rarity and limited evidence for communicability. However, the clinical
implications of environmental contamination with Nocardia spp. in healthcare settings may
need to be reconsidered. For example, Rahdar et al found evidence of 25 Nocardia spp. isolates
from 63% of Iranian hospitals that were sampled (37).

Incidence
Current knowledge of nocardiosis incidence in the United States is based on an historical
survey of 171 infectious disease physicians from 1974 and isolates received at the CDC
reference lab (1). This extrapolated estimate was 500-1,000 new cases annually, which has
been referenced frequently and recently (67, 126) despite changing demographics of the
population (19), increasing numbers of immunocompromised adults (20), longer survival (127)
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and greater occurrence of higher risk conditions (based on Organ Procurement and Transplant
Network data as of January 17, 2019), and improved laboratory methods (18).
Although there are no current national-level estimates of nocardiosis incidence or
prevalence for the United States, there are many prevalence estimates among special patients
at specific facilities. A retrospective study from a transplant facility calculated an overall
prevalence rate of 0.6% among their transplant patients; by organ type, rates ranged from 0.1%
among liver transplant patients to 3.5% among lung transplant patients (11).
Globally, reports are in conflict whether nocardiosis incidence is increasing or remains
stable (28). In Japan, a population-based analysis of isolates from 1992-2001 found the raw
count to be trending upward (128), but they did not account for population growth. A study
from Quebec reported increasing incidence (98), while two studies from Spain reported a stable
incidence (115) and a non-significant positive change (34).

Risk factors among the Immunocompetent
An estimated 60% of infections occur in immunocompromised individuals, and 40% are
reportedly immunocompetent (79, 129). However, it is estimated that 10% or fewer infections
occur in immunocompetent individuals without any risk factors (38, 68), such as chronic lung
disease, on long-term corticosteroids, or have other underlying conditions that may predispose
them to a lung infection (28, 65, 67). More specifically, these include chronic obstructive
pulmonary disease (63), bronchiectasis (28), and cystic fibrosis (67, 130).
In one review of 59 cases of pulmonary disease, 88% had some sort of underlying
pulmonary condition, including structural changes to the lung, but most were considered
immunocompetent (65). Structural changes to the lungs (28, 63) may impact the respiratory
immune response (131), as can ageing (131), which may increase the risk of pulmonary
nocardiosis among adults 65 and older. A recent study has found an association between
disseminated nocardiosis among immunocompetent individuals with granulocyte macrophage
colony-stimulating factor autoantibodies (132). This association requires additional research
but may help explain the ability of nocardiae to overtake an apparently healthy immune
system. The remainder of immunocompetent nocardiosis cases are likely exposed to the
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bacteria by inoculation (44) leading to cutaneous infection, or nosocomial exposure leading to
arthritis (93, 95, 96) or eye infections (36).

Corticosteroids
Nocardiosis has been associated with the use of oral and inhaled corticosteroids (5, 28,
34). This association is not restricted to Nocardia spp.; a similar correlation has been found with
non-tuberculosis Mycobacterium pulmonary infections (133). It is not clear the extent of the
impact of lung structural changes compared to prolonged corticosteroid use, since many
patients with structural changes are on extended corticosteroid use (63). One study of 31
pulmonary nocardiosis cases found seven (23%) cases had COPD, 4 of whom were on prolonged
steroids, and 20 cases overall (64.5%) had prolonged steroid use (33). In another study,
immunocompromised patients with prolonged corticosteroid use had a much higher mortality
compared to both immunocompetent and immunocompromised patients not taking
corticosteroids (85%, 15%, and 20% respectively) (71). Improvements in targeted
immunosuppressive medications for transplant patients and others have reduced the use of
broad corticosteroids (11), which may be a factor in reports of decreasing infections among
transplant recipients (10, 109).

Risk factors among the Immunocompromised
Conditions that affect cell-mediated immunity dominate the risk factors for nocardiosis
among the immunocompromised (48). The immune response to nocardiae begins with innate
immunity; first, monophils and neutrophils phagocytize most nocardiae and inhibit their
growth, although the nocardiae are not destroyed (134, 135). Adequately functioning Tlymphocytes are then required to directly contact the nocardiae, causing subsequent lysis and
killing of the bacterium (136), which prevents pulmonary or systemic nocardial infection.
However, adequately functioning cell-mediated immunity may aid in the development of
mycetoma granulomatous inflammation (42).
Transplant
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Solid organ and hematopoietic stem cell transplant (HSCT) recipients are at greater risk
of bacterial infection due to induced immunosuppression required to prevent rejection (5, 137,
138). Transplant recipients remain at risk despite more precise effects of anti-rejection drugs on
the cell-mediated immune system compared to older medications, such as azathioprine (10,
126, 138).
The prevalence among heart transplant patients ranges from 0.65% (129, 139) – 2.5%
(11), although historical reports show rates of 13% when patients received azathioprine for
immune suppression (10, 113). Peleg et al also calculated nocardiosis rates by organ transplant
types: kidney (0.2%), liver (0.1%), small bowel/multi-visceral (1.3%), and lung (3.5%) (11). Rates
reported in Spain are similar, although lower among lung transplant patients (renal [0.26%],
hepatic [0.18%], and lung [1.78%]) (129). Yet, multiple reports support higher rates of infections
among lung transplant patients compared to other organ transplants (129, 140, 141).
Nocardia spp. infections have occurred months to years after receipt of the transplant
(129, 137, 142). Although Peleg et al found that 63% of transplant recipients developed
nocardiosis within one year of transplant (11), a multisite study found that only 41% of
recipients had onset during the same time (8). The median time from transplant to nocardiosis
onset was 17.5 months (range 2-244 months), although this varied significantly by organ
transplanted (8). Onset more than three years after transplant occurred in 31.6% of patients
(8), and 14% had onset more than five years post-transplant (11).
Most infections are pulmonary and nodules are a common finding (8, 11, 141).
Extrapulmonary dissemination ranged widely but was more common in transplant patients
than others (5). Dissemination ranged from 20% – 47% (8, 11, 12, 141). Mortality also varied
widely, from 14% (11) to almost 40% (28).
A number of risk factors have been identified beyond immunosuppression. Risk factors
found from two studies include high dose steroid use and high calcineurin inhibitor level in
previous month (11, 142). Additional risk factors include recipient age, use of the
immunosuppressive drug tacrolimus, intensive care unit length of stay following the transplant
(142), and cytomegalovirus infection (11).
Malignancy
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Patients with solid tumors and hematologic cancers are at elevated risk of nocardiosis,
likely due to cell-mediated immunosuppression (13). A surveillance study in southern France
found 22% of cases had a history of malignancy (143). The majority of infections occur in
patients with hematologic cancers (54.5-64%) (13, 14) followed by solid tumors (36-43.9%) (13,
14). Patients have frequently received either stem cell transplants (35.6%) (14) or bone marrow
transplants (31%) (13). In a cancer population, nocardiosis frequency appears to be increasing
over time—infections averaged 3.3/year from 1988-2001 (13), 4.6/year from 2002-2005, and
16.4/year from 2006-2012 at a cancer facility (14). Incidence during the first period was
60/100,000 patients with the highest incidence among bone marrow transplant recipients
(701/100,000 patients) (13); incidence was not published for the latter time periods (14). The
increasing frequency has been ascribed to improved testing, recognition, and survival among
cancer patients (14).
Cancer patients may also be at risk because nocardiae can compose biofilms on central
venous catheters (CVC) (125). Such growth can lead to central line-associated blood stream
infections (CLABSI) (125), and may be related to disseminated bacteremia in patients with CVCs
(110, 125). Although these infections appear to be rare, those with CLABSI had better outcomes
than those with disseminated infection, including shorter hospital stay and lower mortality
(125).
Nocardiosis symptoms, such as fever, may not be present due to immunosuppression
(14). Additionally, abscesses can be difficult to differentiate from malignancies (7), and may be
confused as metastasis of an existing cancer (144). This is particularly true for CNS infections in
patients with cancers that frequently metastasize to the brain, which can delay diagnosis and
may affect prognosis (144).
HIV
Human Immunodeficiency syndrome (HIV) is a risk factor for nocardiosis owing to its
impact on cell-mediated immunity (48). Although HIV may be the primary risk factor in many
cases, in one study, half of the patients also had chronic lung disease (115). Reported all-cause
mortality from older studies was 63% (111) and 67% (114). More recent reports indicate that
nocardiosis is less frequent in HIV-positive persons possibly as a result of prophylactic
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trimethoprim-sulfamethoxazole to prevent Pneumocystis infections (126). However, this
prophylaxis may not provide adequate protection against nocardiosis (5, 12).
There are a few estimates of nocardiosis prevalence among HIV-infected individuals. A
few articles that are frequently referenced report cases from the 1980’s (111, 114, 145) when
the demographics, care, and prognosis was vastly different for HIV-positive patients compared
to today (127). These estimates range from approximately 0.3% (114, 145)-1.8% (111). In Spain,
a report found an incidence rate of 0.38% (115), while one study in Côte d’Ivoire found a
nocardiosis prevalence of 4% among patients who died of AIDS (32).
Injection drug use is commonly reported among cases with HIV and nocardiosis. In
Uttamdani et al, 53% of HIV-positive nocardiosis cases were injection drug users (IDU),
compared to 30% among the HIV-positive patients who received treatment at the same time
(111). Cases also frequently had onset of AIDS concurrent with the nocardiosis infection or
within the previous six months (60%) (111).
Pulmonary nocardiosis can be mistaken for tuberculosis (7), and tuberculosis and HIV
are frequent co-infections (146). Among ten patients who were diagnosed post-mortem with
nocardiosis, 40% had been incorrectly diagnosed with tuberculosis prior to death (32). Of HIVpositive patients presenting to a chest clinic for suspect pulmonary tuberculosis in Sudan, 1.2%
were diagnosed with nocardiosis (29); 2.9% of HIV-negative patients at the same chest clinic
also had nocardiosis, but 94% of patients had a risk factor for nocardiosis (29). Another study
that also evaluated patients with suspect pulmonary tuberculosis in Ghana found 16.7% were
co-infected with HIV and Nocardia spp. while 8.3% were co-infected with HIV and tuberculosis
(147).

Mortality
The mortality rate ranges widely based on the form of disease, the immune status of the
patient, and the era of the publication (48). Most reviews focus on all-cause mortality rather
than deaths definitively due to nocardiosis. Factors that are associated with mortality include
acute disease (64, 68, 71, 110), involvement of two or more organs (42, 71, 110), severe
immunosuppression (71), and greater disease severity (68).
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Primary cutaneous disease without dissemination has the lowest risk of death (4). Most
individuals with primary cutaneous nocardiosis recover fully (3, 43, 53), although there have
been some cases in which primary cutaneous infection disseminates and results in death (3).
Patients with bacteremia have a mortality rate of ~50% (110), and the rate among patients with
disseminated infections range from 44% (42) -85% (71). CNS involvement, whether primary or
secondary infection, has a poor prognosis and mortality of almost 50% (6).
Underlying conditions are also associated with higher mortality rates. Patients with
malignancies have a mortality rate greater than 60% (13). Transplant recipients reportedly have
the worst outcomes compared to other immunocompromised and immunocompetent patients
(28). Of 47 transplant patients, fewer than 60% survived at 12 months, while
immunocompetent patients had a survival rate of greater than 90% (28). Another study
reported a similarly high all-cause mortality rate of 37% (129). Other studies report better
survival outcomes of 82% (141) and 6-month survival at 86% (11). Although transplant
recipients are severely immunosuppressed and at greater risk of mortality (148), patients with
nocardiosis have poorer outcomes compared to other transplant recipients, with a comparative
mortality rate of 16.2% vs. 1.3% (142).
Finally, mortality may have decreased over time. Cases in the literature before 1950 had
a mortality rate of 70%, which dropped to 44% between 1950 and 1979 and 26% between 1980
and 1994 (42). This finding could also be due to publication bias.

Prevention
Nocardia sp. are ubiquitous in the soil, so there are few techniques to prevent infection
(4). Since a majority of primary cutaneous infections reported a traumatic injury to the skin (3,
53), covering skin or open wounds to avoid direct soil contact may prevent cutaneous
nocardiosis. Wearing shoes may prevent actinomycetoma by preventing small inoculation
injuries to the feet (4); however this has not been systematically examined (149).
TMP-SMX is given to immunocompromised individuals to prevent Pneumocystis
infection (5). Some authors have suggested that this use may provide ancillary protection
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against nocardiosis (110, 126, 150); however, infections concurrent with prophylactic use (5, 12,
141) have led to dispute over its effectiveness for this purpose (142).
Disinfection of a ward following a nosocomial outbreak may be warranted to prevent
future infections (118, 124). Antimicrobial treatment of central venous catheters may prevent
the introduction of Nocardia spp. to an immunocompromised person via biofilm growth (125).
There are no other specific recommendations to prevent Nocardia spp. nosocomial
transmission. However, this may need further evaluation to determine the clinical importance
when Nocardia spp. are found in healthcare settings (37).
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III. Limitations of existing literature and currently available data
There are several limitations in the existing literature that preclude providing an
accurate estimate of nocardiosis incidence, a generalizable description of persons at risk and
risk factors, or evaluation of geospatial associations of nocardiosis in the United States. First,
most publications are case reports or case series with literature reviews. These publications
have a definite value added to the medical community in that they comprehensively describe a
case’s history, the clinical and microbiological findings, treatment, and outcomes. Additionally,
these publications provide detailed descriptions of interesting and new presentations, such as
nocardiosis following knee surgery (95), infections with newly identified Nocardia species (151),
or unique presentations (152).
A primary limitation to these articles is publication bias. Cases that are reported in the
literature are interesting or unique in some way to warrant the time to be reported and
published (153). They are also limited in generalizability, since the case series are typically
described from a single facility where patient demographics, geographic influences, and even
underlying conditions lack variability (5, 126, 154).
Second, there are a few published multisite studies, but they are not representative of
the U.S. population. Some of the studies target high-risk patients at specialty facilities, such as
organ transplant recipients at transplant hospitals in Western Europe (8), or patients with cystic
fibrosis (130, 155). Some national laboratories have published reports of specimens received
for identification, along with associated epidemiologic information (2, 21, 55, 156); however,
these are likely limited by reporting bias due to non-random specimen submission (2, 157), and
selection bias due to submission for severe or unique cases (157).
For example, following a 10-year report by CDC describing 765 Nocardia isolates
originating from humans (2), two other studies described 2,650 isolates from six clinical
reference laboratories across the United States (16, 17). This demonstrates that the CDC
publication lacks national representativeness of nocardiosis cases in the United States, which
cannot be remedied by the use of current epidemiologic surveillance data because nocardiosis
is not under national surveillance (158).
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Third, many publications describe the current incidence of nocardiosis to be
approximately 1,000 cases per year, referencing a survey of infectious disease physicians from
1972-74 (1). Yet, this estimate is likely a substantial underestimate for several reasons.
Improvements in microbiological and molecular methods have improved the ability to
accurately identify and differentiate Nocardia species (21, 159). The genus continues to expand
and change taxonomically with the assistance of these new techniques (15), which may prevent
misdiagnoses. The population at risk has also increased because the number of adults living
with immunocompromising conditions has grown (20). Survival has improved among people
with immunocompromising conditions, including HIV (127) and cancer (14). In addition, three
times the number of transplants were performed in 2018 compared to 1988 (based on OPTN
data as of January 17, 2019). Finally, the population of older adults has increased in the United
States (19), who are also at greater risk of infections in general (160) and nocardiosis in
particular (65).
There are also limitations to the available data. Because nocardiosis is rare, prospective
cohort studies are usually not feasible, and the logistics and expense of multi-site studies can be
challenging. These reasons likely drive the popularity of facility-based retrospective studies
using medical chart or record review (5, 11, 14). Medical records could not be evaluated
previously on a large scale for nocardiosis, such as using national hospitalization discharge
databases (105), because nocardiosis was combined with other etiologic agents in the same
code within the International Classification of Diseases 9th revision-clinical modification (ICD-9CM). Nocardiosis was given a distinct diagnosis code in the 10th revision (ICD-10-CM) (161),
which went into effect on October 1, 2015 for all medical billing in the U.S..
Although nocardiosis diagnoses are collected as a distinct diagnosis code, analyses are
still limited. The cost of several large population-based administrative data sources, such as
IBM’s MarketScan (162), Chronic Conditions Warehouse via the Centers for Medicare and
Medicaid Services (163), and databases from the Healthcare Cost Utilization Project (HCUP)
(105), can be prohibitively expensive. Additionally, compiled and cleaned databases can take a
few years to complete and make available to researchers, which may be further limited by data
sharing agreements. HCUP data are visit-based, which can limit the interpretations of the data,
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while Medicare data are person-based yet are expensive, complicated, and have strict access
and data use agreements. With limited population-level data availability, potential analyses are
limited until a future time when there are sufficient data. However, analyses using the currently
available data will establish a baseline on which future studies can build.

IV. How research will enhance field
Problem statement
There are limited population-based data in the literature regarding nocardiosis. The
disease is potentially increasing, as the number of people who are potentially at risk or have
pre-disposing risk factors continues to rise (19, 20, 127, 160). Information that is published is
often based on case series from specific facilities, which may limit the generalizability due to
population differences based on geographic, social, and environmental characteristics. The
published multi-center studies are often limited by a narrow scope of the patients (8, 164) or
non-spatially representative selection of participating facilities (27, 30, 77, 143). The results
from these studies may have high internal validity to the risk group or site locations but may
lack generalizability to other populations and are not representative of nocardiosis in the
United States.
Epidemiologic studies published by national reference laboratories (2, 156) may be
biased also. Selection bias may be present in laboratory surveillance (157), since isolates may
be sent for seriously ill patients, those who failed treatment, or had a unique presentation.
Reporting bias (e.g., selective submission) may be present if state or provincial laboratories do
not send specimens to the reference laboratories for diagnosis (2, 157).
A population-based analysis of nocardiosis to describe clinical characteristics, estimate
survival rates, and evaluate known nocardiosis risk factors and spatial characteristics will
contribute the first U.S.-representative description of nocardiosis in the literature. The findings
may further improve clinical recognition of nocardiosis based on case characteristics and
underlying risk factors that are associated with infection. Improved clinical recognition may
prompt appropriate and targeted diagnostics, which ultimately improves the rapid provision of
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appropriate antimicrobials and overall outcomes (15). Finally, this approach may guide future
research activities from findings that may warrant further exploration.

V. Statement of purpose
Purpose of the research
The purpose of my research is to evaluate the clinical and spatial characteristics of
nocardiosis in the United States using population-level data. This will be the first nationallyrepresentative description of nocardiosis in the country, and the first using medical billing data
for nocardiosis.

Justification
This research will address limitations in the literature. First, few large-scale case
descriptions exist that are not limited by reporting bias or limited generalizability of case
reports (153). Second, many studies describe cases from one or a few facilities, which limits the
generalizability of the descriptions (5, 126, 154). Third, even large-scale reports may have
reporting bias (2, 16). Finally, many more variables and more complete data are available
through medical coding compared to laboratory surveillance data. This is the first populationbased analysis of nocardiosis clinical characteristics, risk factors, costs, and incidence estimates.
It will also establish a baseline against which future studies can be compared to evaluate
disease trends.
Additionally, this will be the first evaluation of the geographic distribution of nocardiosis
in the United States using a population-based approach. Current literature indicates there may
be some geographic differences in distribution of either disease or nocardia species (2, 38, 165);
however, it is not possible to determine if differences are associated with the disease, the
etiologic agent, or due to reporting or selection bias. Using both spatially and nationally
representative data, these biases are reduced.
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Research questions and hypotheses
The first research question is: who is affected by nocardiosis? I hypothesize that
nocardiosis will occur more frequently among Medicare Fee-For-Service (FFS) recipients who
have known nocardiosis risk factors or other co-morbidities. The first aim is to describe the
disease and patient characteristics, including demographics, diagnoses, severity, treatment,
cost, and insurance payer type. The second aim is to describe risk factors and chronic conditions
and evaluate the impact of known nocardiosis risk factors on patient outcomes.
The second research question is: what is the incidence of nocardiosis in the United
States? I hypothesize that the incidence will be substantially greater than the frequently cited
incidence rate of 1,000 cases per year (1), and the rate will be greater among Medicare
beneficiaries and persons with more comorbidities.
The third research question is: what factors are associated with mortality among each
study population? As a subset of this research question is which comorbidity measure is the
most predictive of mortality among nocardiosis-associated hospitalizations in the US?
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Chapter 2: Methods
I. Study design
This study is a secondary analysis of administrative discharge and beneficiary data to
evaluate patient, clinical, and spatial characteristics of nocardiosis in the United States since the
implementation of ICD-10-CM coding in October 2015. The first population studied were
beneficiaries receiving Fee-for-Service (FFS) Medicare through the Centers for Medicare and
Medicaid Services (CMS); the 100% FFS data available through the Chronic Condition
Warehouse (CCW) Virtual Research Data Center (VRDC) from October 2015- March 2018 was
used (163). The 100% FFS Medicare data are person-based records of all Medicare beneficiaries
who receive FFS care in the United States; all files are linked using a unique beneficiary ID
without direct identifiers; access was allowed under a CDC-CMS Interagency Agreement (IAA)
and use was restricted under a strict data use agreement.
The second population studied was 100% of inpatient and ambulatory surgery
discharges from participating states available through the State Inpatient Databases (SID) and
the State Ambulatory Surgery and Services Databases (SASD) from HCUP, available from
October 2015- December 2017. The HCUP files are visit-based records of hospitalizations or
surgical discharges and are de-identified files available to CDC through an IAA with restricted
use under a data use agreement.

A. Subjects and settings
Chronic Condition Warehouse (CCW) Medicare data
The Medicare inpatient, outpatient, carrier (physician billed) claims data were combined
with the Master Beneficiary summary dataset containing demographic and coverage
information, and the chronic condition files containing pre-coded chronic conditions (163).
Access to the CCW VRDC ended on October 31, 2018; all analyses of this source were
completed on or before that date. Analysis errors cannot be remedied, nor could additional
analyses be performed after that date.

Case Definition
36

To create the nocardiosis-associated numerator, the following research identifiable files
(RIF) were utilized for October 1, 2015- March 30, 2018 unless otherwise stated.
•

For outpatient institutional visits:
o RIF outpatient claims

•

For clinician billing accompanying an institutionalized visit:
o RIF carrier files

•

For inpatient institutional visits, due to changing data structure and organization:
o MedPAR (only available October 1, 2015- December 31, 2016)
o RIF Inpatient claims (January 1, 2017- March 30, 2018)

•

For Parts A-D coverage, HMO coverage, and date of death:
o Master beneficiary summary file (MBSF)

•

For select chronic conditions identified by the CCW:
o MBSF chronic conditions
o MBSF other chronic conditions (October 1, 2015- December 31, 2016).

CMS beneficiaries were considered a nocardiosis “case” if they had at least one
inpatient or outpatient ICD-10-CM Claim Diagnosis of A43 (nocardiosis) (161). The CCW
inclusion criteria for chronic conditions were used to define inclusion of carrier file visits (166).
That is, a carrier visit must be accompanied by an institutional claim (i.e., inpatient or
outpatient) or a beneficiary had more than two carrier visits with any-listed diagnosis of A43
more than 30 days apart.

Repeated visits
All visits by the same beneficiary with a nocardiosis diagnosis within 30 days were
classified as ‘related’. Related visits accounted for multiple billing claims, transfers, and provider
claims during an institutionalized visit. Analyses of demographics were performed on unrelated
visits, while evaluation of costs and presence of co-morbidities were performed on the
complete dataset containing all encounters with any-listed nocardiosis that met the inclusion
criteria.
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Denominator
Beneficiaries with any Health Maintenance Organization (HMO) coverage were excluded
from the denominator because they do not have a claims history during their HMO enrollment .
After removing all beneficiaries with any HMO coverage, a Medicare population denominator in
person-months was calculated for beneficiaries with Medicare FFS enrollment between
October 1, 2015- March 30, 2018. State person-month denominators were the summed
person-months by the beneficiary state of residence at the start of each calendar year.
Beneficiaries may contribute person-time for multiple states, but not in the same years.

Healthcare Cost and Utilization Project (HCUP)
The SID and SASD available from HCUP includes 100% of inpatient discharge records
from participating states (105). The SID data containing ICD10 discharge records are available
from 29 states in 2015 (October-December), 26 states in 2015-16, and 13 states from 2015-17.
The estimated US population included in the inpatient analysis in 2016 is 152,453,663, 47.2% of
the total estimated US population in 2016 (167). The SASD data are available from 14 states in
2015 (October-December) and 15 states in 2016; 7 states have data available from October
2015- December 2017. The estimated US population included in the ambulatory visits analysis
in 2016 is 92,675,765, which is 28.7% of the total estimated 2016 population (167).
HCUP data are visit-based, thus these data cannot evaluate person-level characteristics;
the same person may make multiple visits, which will appear as separate records. However, SID
and SASD include people of all ages from all payers, which can be a useful contrast to the older
FFS Medicare group described above.

Case Definition
A nocardiosis-associated visit was defined as the presence of the ICD-10-CM claim
diagnosis of A43 (nocardiosis) (161) listed anywhere in up to 25 diagnosis variables (168, 169).
By searching for ICD-10-CM codes, the visits will be restricted to those that occurred on or after
October 1, 2015.
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The primary diagnosis, which is located in the first diagnosis variable, will be analyzed
separately to determine the frequency that nocardiosis is the principal diagnosis for a visit. SID
and SASD visits were evaluated on the same variables as the Medicare FFS when available, as
well as insurance type, urban/rural, and chronic disease risk factors listed on the visit record.
The study will also evaluate form of nocardiosis, associated risk factors, co-morbidities, medical
costs, healthcare payer, and calculate nocardiosis-associated hospitalization rate and rate ratios
by demographic groups.

Denominator
Rates were calculated using bridged-race population estimates from the National Center
for Health Statistics as the population denominator (167). The census population estimates
were included for each year that a state participated. These denominators were used to
calculate both person-year denominators and hospitalization rates per 100,000 person-years.

B. Human Subjects
The CCW analysis was determined to be non-human subjects research by the CDC
Human Subjects Protection Office, and the project was approved by CMS RESDAC. The HCUP
data analysis was also determined to be non-human subjects research by the CDC Human
Subjects Protection Office. The project was approved by the CDC Data Hub within the Center
for Surveillance, Epidemiology, and Laboratory Services, the administrator of HCUP data at CDC.

II. Definitions and measures
Any strata cell sizes <10 were restricted and analyses were not done based on data use
agreements for both data sources. Definitions for specific variables of interest are described
below. The definitions apply to both datasets unless indicated.

a) Disease Type
Pulmonary, cutaneous, and disseminated nocardiosis were defined first using specific
ICD-10-CM codes for pulmonary (A430) and cutaneous disease (A431) as listed in diagnosis
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fields for each claim (161). Then, diagnosis and procedure ICD-10-CM codes indicating
pulmonary, cutaneous, disseminated, or CNS disease were searched within each claim (Table
2.1). Disease form was then assigned to each claim; ‘not specified’ was assigned when disease
form could not be determined. The most severe disease form was kept for each beneficiary;
when more than one form was identified, the claim was categorized as disseminated disease
(170). Erroneously, primary CNS infection was not evaluated in Medicare FFS data and could
not be remedied due to data access restrictions. Primary CNS was evaluated in HCUP data.

Risk Factors and Co-morbidity Measures
CCW Medicare data
The earliest CCW Medicare claims data began on January 1, 1999. The MEDPAR, RIF
outpatient and carrier, and the MBSF files from January 1, 1999 - September 30, 2015 were
used to find chronic conditions and known nocardiosis risk factors existing at any time between
Medicare FFS entrance or January 1, 1999 and the nocardiosis diagnosis. Twenty-two
conditions were selected as nocardiosis-specific risk factors; these conditions have been
described frequently in the literature as occurring or associated with nocardiosis, and some are
associated with poorer outcomes in nocardiosis case series (6, 8, 14, 65, 129). Nine of the
selected risk factor conditions were already coded in MBSF Chronic Conditions and Other
Chronic Conditions datasets (166). The ICD-10-CM (161) and ICD-9-CM (9) diagnosis and
procedure codes for the remaining conditions were compiled from the the Charlson comorbidity index (CCI) (171), the American Thoracic Society (172), additional literature searches,
and reviewed by committee member H.W. (Appendix Table A.1).
For years 1999-2016, the select pre-defined and pre-coded conditions available in the
MBSF Chronic Conditions files were used (i.e., diabetes, chronic obstructive pulmonary disease,
chronic kidney disease, cancer, anemia, alcohol addiction, tobacco use, HIV/AIDS, and cystic
fibrosis). The Chronic Conditions files were not available after 2016, so the pre-defined ICD-10CM codes were used to search all Medicare claims records for each nocardiosis case in 2017
and 2018for those same conditions. The extensive period was included for risk factors due to
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reports of nocardiosis onset more than three years after solid organ transplant (8, 11), and the
potential for many of the risk factors to be long term chronic conditions.
To calculate the CCI score, the conditions for the CCI were searched in the claims files of
nocardiosis cases in the 12 months prior to the first nocardiosis diagnosis using the Quan et al
modified codes (171). The Charlson weights were used (173).

HCUP
The same risk factor and CCI codes (171) were used as discussed above and listed in
Appendix Table A.1; however, because the datasets are visit-based and not person-based, the
risk factors could only be applied to diagnoses or procedures listed during a single nocardiosisassociated visit, rather than in the 12 months or more prior(171). Both analyses of risk factors
and CCIs will substantially underestimate the presence of these selected conditions if the
existing chronic conditions are not reported during the visit, and will inflate the count if the
same patients with several conditions have many repeated visits.

In addition to the Charlson comorbidity index and nocardiosis-specific risk factors, the
Elixhauser comorbidity index and the Chronic Condition Indicator were evaluated using the
HCUP data. These measures have been developed or optimized for administrative data in
general (174, 175) and particularly for HCUP (176). The Elixhauser algorithm contains 30
comorbidities that are associated with longer length of stay, hospital charges, and mortality;
however, the authors who developed this measure do not recommend collapsing it into a single
count as it can differ by age and other patient characteristics (174). Instead, the Elixhauser
conditions are included in a regression model with demographic factors to create scores to
estimate readmission and mortality.
The Chronic Condition Indicator classifies each diagnosis code into a chronic or nonchronic condition and is an expansion of Hwang et al’s methodology for inclusion of more ICD9-CM codes (176, 177). The indicator is then summed across all diagnoses listed for a visit to get
the total count of chronic conditions. Both comorbidity measures are beta versions for ICD-10-
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CM codes, both measures have been used in published reports using ICD-9-CM codes, although
Elixhauser has been used more extensively (178, 179).
The various comorbidity measures can be compared to evaluate predictors of death and
disseminated nocardiosis, which has not been done before for nocardiosis. Often, these
measures are used to evaluate outcomes of all patients in a specific setting (e.g., ICU) (180), and
are frequently used to evaluate cardiovascular disease (179), but rarely infectious diseases.
However, due to the opportunistic nature of nocardiosis, comorbidity measures may be
appropriate to assist with predicting mortality.

Costs/Charges
CCW Medicare data
Among Medicare FFS, costs per visit and per beneficiary for all nocardiosis-associated
visits were calculated by summing the following CCW variables: ‘claim payment amount’;
‘indirect medical education and provider payments’; ‘Part A’ and ‘Part B coinsurance’ amounts;
and ‘blood deductible’ from inpatient, outpatient, and carrier visits. For inpatient visits, ‘claim
per diem’ amount was multiplied by the days of hospitalization and added to the previously
listed costs (181).
HCUP
Costs for nocardiosis-associated visits in SID and SASD were converted from the variable
total charges using the HCUP cost-to charge ratio files to represent the actual amounts paid
versus the amount billed (182).

Mortality
Definitions: CCW Medicare data: For Medicare FFS beneficiaries classified as
nocardiosis cases, death was counted if it occurred within 365 days of the first nocardiosisassociated visit, or 12-month all-cause mortality.
HCUP: Death was counted for SID and SASD visits if the patient died during
hospitalization or “expired” was reported in the visit record (105).
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1

Table 2.1: ICD-10-CM codes used to define disease type
Name

ICD-10-CM codes

Additional Rules

Cutaneous

A431, R21, H16,H15,h43,H04, H10,B42,K04,L02, L03, R22,
L04,L08,L10, L11,L29, L52, l92,L97,L98,L99,R238, G245,
H2005,H5314,L03213
A430, R91,J15,J16,J17,J18, J85,J86,J90,J91,J92,J93, J94, J96,
R05,R06,R942,R093,R042,R072,R0902,R0989
R4781,R29810,h4400,h4419,R7881,L0221,G9389,h31,h33,I
88,J01,J32,M71,H16,J36,J39,K63,M86,N15,N30,R11,R61,R6
5,R93,R270,R471,R579,E278,K046,
K047,K651,R060,,D733,K750

-

Pulmonary
Disseminated

Mycetoma
Neurological
involvement

B471
R51,R56,R40,R46,R41,R42,R43,R44,R45,R90,G04,G05,G07,
G934,G939,R940,G060,G062

Presence of >1 form of nocardiosis
• A43.1 + A43.0 on one or more record for
a beneficiary
• Diagnosis claims for >1 form identified
from specified ICD-10-CM codes
If no other form of nocardiosis listed, then =
primary CNS infection

2

3
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Chapter 3: Data Analysis and Results

5

I. Analysis

6

Methods and Rationale

7

Descriptive analyses were performed on the CCW Medicare data and the HCUP data.

8

Analysis of the CCW Medicare data evaluated person-level characteristics and characteristics

9

aggregated to the state of residence. The data were evaluated by demographics, Medicare

10

coverage, chronic conditions and risk factors, duration of hospitalization, costs, diagnoses,

11

procedures, and disposition. Analysis of the HCUP data will evaluate visit-level characteristics,

12

length of stay, urban/rural residence, and disposition. All cell sizes <10 were suppressed per the

13

data use agreements with both HCUP and the CCW.

14

Both person-level and visit-level analyses are presented using frequencies and percents

15

or means and standard deviations, as appropriate. Medians are not allowed to be presented

16

from the CCW Medicare data per the data use agreement, as the value could potentially be a

17

result for a single person. For consistency in reporting, means will be presented for HCUP as

18

well unless the data are substantially skewed, in which case medians and ranges are also

19

reported. To evaluate common diagnoses, diagnosis codes from all visits were appended for

20

each case and searched; the 50 most common diagnoses were identified.

21

Correlations were calculated using Pearson’s correlation coefficients to evaluate

22

bivariate associations and collinearity; Spearman’s rank correlation was used to evaluate

23

correlation between categorical variables. Disease incidence was calculated from the Medicare

24

FFS using the number of cases divided by the total person-years of beneficiaries who had

25

Medicare coverage, no HMO coverage, and occurred between October 1, 2015 and March 31,

26

2018. Average annual visit rate per 100,000 persons were calculated from HCUP data, Poisson

27

regression with a robust error variance was used to calculate rate ratios from HCUP data, a

28

modified Poisson which does not overestimate the confidence intervals (183).

29
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30

Mortality

31

Kaplan-Meier survival curves evaluated all-cause mortality after the first-listed

32

nocardiosis diagnosis within the CCW, the curves are shown through 12 months following the

33

first diagnosis (184). Multi-collinearity was evaluated with Pearson’s correlation. Differences in

34

survival curves were assessed using the log rank test assuming no differences earlier in the year

35

(185). Additionally, Cox proportional hazards models were calculated to evaluate the statistical

36

association of demographic and co-morbidities on time to death (186). The smallest Akaike

37

Information Criterion (AIC) was used to select the final model (185).

38

The ability of each of the comorbidity measures to predict mortality would be a useful

39

factor when interpreting the associations of these indexes for nocardiosis cases, and to build a

40

mortality model. Such an evaluation must be restricted to the HCUP SID data because of the

41

larger sample size compared to SASD, and the implementation of the four different measures in

42

HCUP and not in Medicare data. To evaluate whether the measures are collinear, and therefore

43

a comparison between them would be inappropriate, correlations were assessed with

44

Pearson’s pairwise correlation and then collinearity was assessed using the variance inflation

45

factor and tolerance.

46

Demographic variables are potential confounders of mortality and were evaluated for

47

inclusion in the baseline model, to which the comorbidity measures would be added. The

48

demographic variables included in the baseline model were age, race, region, urban residence,

49

median income from patient zip code compared to the state, and sex; age was categorized due

50

to a skewed distribution. There was no variable of hospital type for a hospital-level indicator, so

51

urban/rural was used as a proxy.

52

Each comorbidity measure was added individually to the baseline model with the

53

outcome ‘died’; performance of each model was compared using the AIC and c-statistic as has

54

been done previously (187, 188). A single comorbidity measure was selected with the lowest

55

AIC and highest c-statistic. This model serves as the base to build the logistic regression model

56

to explain mortality.

57
58

There are many comorbid conditions that are potential moderators of nocardiosisassociated mortality. Only comorbidities that were potentially associated with mortality (p<0.2)
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59

on bivariate analysis and were not in the retained measure were included. Conditions that were

60

present in the retained measure and another comorbidity measure were also evaluated if the

61

frequency varied substantially between measures (e.g., renal disease between Charlson and

62

Risk Factor measures), since some use a different combination of ICD codes. The conditions that

63

were present in more than one measure and had a p-value of <0.20 were further evaluated for

64

correlation using Spearman’s rank-order coefficient for categorical variables; conditions that

65

were not highly correlated with the similar condition in the retained measure were included in

66

the multivariable model building. Comorbidities that met the above criterion on bivariate

67

analysis were excluded from the model if cell sizes were less than 10. The AIC and Hosmer-

68

Lemeshow Goodness of Fit criteria were used to evaluate fit, and the highest Hosmer-

69

Lemeshow Goodness of Fit result was selected as the final model.

70

State Aggregated Analyses

71

Characteristics of the nocardiosis cases in the CCW Medicare data and visits in the HCUP

72

data were aggregated to the state of residence of the case or of the patient who made the visit.

73

Medicare CCW data collects state of residence during each month of the year; to account for

74

Medicare recipients who move between states (e.g., snowbirds), the monthly state of residence

75

was used to calculate the cumulative person-years per state. This cumulative population was

76

used as the denominator to calculate incidence for each state.

77

The SID contains 100% of the inpatient discharges from each participating state,

78

although each state has participated for varying amounts of time during the 2.25-year study

79

period. The post-censal population estimates (167) for each year a state participated in SID was

80

used to calculate cumulative person-years as the denominator, which was used to calculate the

81

average annual hospitalization rates for each state or jurisdiction. Standard errors were not

82

calculated because the SID and Medicare CCW contain complete data.

83

Analytical Tools

84

SAS Enterprise Guide 7.1 (Cary, NC, USA) was used for all analyses within the CCW

85

Virtual Research Data Center. The HCUP data were analyzed in SAS 9.4 (Cary, NC, USA) (alpha

86

=0.05). QGIS 2.18.1 (Boston, MA) was used to map the aggregated state-level incidence and

87

hospitalization rate.
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88

II. Results
Patient demographics

89
90

Medicare

91

Between October 1, 2015 and March 31, 2018, 3,167 individual Medicare FFS cases met the

92

inclusion criteria for nocardiosis. This was a rate of 3.3 incident cases per 100,000 case years. A

93

disproportionate number of cases were identified in the last quarter of 2015 compared to the

94

other periods.

95

While 70.2% of nocardiosis cases were between ages 65 and 84, 19.5% were younger than

96

65 (Table 3.1). This is consistent with overall enrollment in Medicare FFS, which the average

97

enrollment by these age groups between 2015 and 2017 was 71.6% and 16.6%, respectively

98

(Table 3.1)(189). The ratio of males to females is about 1.1: 1, and a majority were White

99

(83.3%).

100

Cases with dual Medicare and Medicaid coverage were younger compared to those

101

without. This finding was consistent with the entire Medicare FFS population in which 44.3%

102

with dual coverage were younger than 65 compared to 10.1% without dual coverage (190, 191).

103

Dual coverage differed by race as well (57.3% white with dual coverage, and 89.4% without).

104

These discrepancies were almost the same proportions as in the entire Medicare FFS

105

population except for Hispanic cases, in which the proportion with dual coverage and

106

nocardiosis was 8.3%, compared to 14.0% in the full population (190, 191). Disease type did not

107

differ substantially by dual coverage, thus being lower income may not have an impact on type

108

of infection, and by proxy, severity.

109

The original reason for enrollment differed between nocardiosis cases and all Medicare

110

cases. A greater proportion of Medicare cases with nocardiosis received Medicare coverage

111

because of disability and/ or End Stage Renal Disease (ESRD) compared to all of Medicare

112

(32.5% vs 17.1%). A higher frequency of nocardiosis cases were sicker and joined Medicare at a

113

younger age than all FFS Medicare cases. There were more disseminated infections in cases

114

with ESRD (χ2=9.8, df=3, p=0.0201), and the proportion of disseminated infections were seven

115

percentage points higher than among those without ESRD (58.0% vs 51.0%), thus a deeper look

116

into the characteristics of these cases is warranted. Males with nocardiosis had a higher
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117

occurrence of ESRD than females (68.7% with ESRD, 50.3% without) (χ2=36.7, df=1, p<.0001).

118

This discrepancy was also seen in the entire Medicare FFS population; however the difference

119

was less extreme with males comprising 57.7% of ESRD cases and only 46.4% without ESRD

120

(χ2=1503.2, df=1, p<.0001) (192). Age was also highly skewed to younger age groups for those

121

with ESRD, while the majority of cases without ESRD were 65-84 years old; 61.9% of ESRD cases

122

were younger than 65 compared to 17% without ESRD. This discrepancy was similar to all

123

Medicare FFS but at a smaller magnitude (53.7% were younger than 65 with ESRD, 16.2%

124

without) (192).

125

There were also racial disparities among cases with ESRD (χ2=265.6, df=4, p<.0001); African

126

Americans were disproportionately affected (29.3% of cases with ESRD vs 5.4% without),

127

although the expected counts of ESRD were greater among all non-White race categories. Yet

128

again, the similar disparity was found among all Medicare cases. These differences in cases with

129

nocardiosis compared to all Medicare cases indicate a relationship between males and younger

130

cases with ESRD and nocardiosis.

131
132
133

State Inpatient Databases
From the 29 states participating in the State Inpatient Databases (SID) from October 2015-

134

December 2015, 274 nocardiosis-associated hospitalizations were identified, in 2016, 898 visits

135

were identified from 26 participating states, and 454 visits from 13 states in 2017 for a total of

136

1,626 visits (Table 3.1). The nocardiosis-associated hospitalization rate was 1.02/100,000

137

population. The hospitalization rate was greatest in the 65-74-year-old age group and is 11.1

138

times higher (95% CI: 9.6-12.75) compared to patients 0-49 years of age. The rate almost

139

doubled in patients 55-59 years old compared to 50-54-year-old patients (0.69 vs.

140

0.35/100,000).

141

Visits occurred among more men than women (61.6% vs 38.4%) and 51.8% were in adults

142

65 and older (Table 3.1). There were few visits among adults 85 and older (n=97) of which

143

53.6% were females, yet in the 2016 population from these participating states, 65% of people

144

85 and older were women (167).
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145

A larger percentage of nocardiosis-associated visits were reported in the Western census

146

region (37.7%, n=613), although 19.1% of the population represented in these data are from

147

the West. The second largest was from the South (32.4%, n=526), while states in the South

148

represented 38.1% of the population in SID. The Northeast had the lowest with 11.1% (n=181),

149

while the proportion of the population in SID from the study period from the Northeast was

150

24.6%. Interestingly, the majority of visits among persons younger than 65 occurred in the

151

South and West (73%, n=578), which was a greater proportion of all visits in the South than the

152

other regions (54.9%). When looking at more granular age groups, 47.1% (n=72) of visits in

153

persons under 35 were in the West and the majority of older age groups occurred in the West,

154

while 37.9% (n=241) of visits of persons 35-64 were in the South

155

Residence in an urban setting was listed for 87.0%, the remainder were in rural or

156

micropolitan areas (193), compared to 78.0% urban dwellers in the total population in the

157

participating states (194). The Midwest was more rural, with 67.7% of visits from residents of

158

rural areas. Median household income state quartile for patient’s ZIP code was relatively evenly

159

distributed among the quartiles (22.1%, 26.5%, 26.0%, and 25.5%), but almost 85% of those in

160

rural areas fell into the bottom two income quartiles.

161

Medicare was the predominant primary payer among the nocardiosis-associated visits

162

(n=317, 64.7%), followed by private insurance and then Medicaid. There were too few self-

163

payers and other insurance coverage to report. Payer type for visits among patients younger

164

than 65 was Medicare (35.5%), Medicaid (23.3%), and Private insurance (37.7%); 60.4% of

165

Medicaid coverage was among adults 35-64, and Medicare was the payer among 23% of visits

166

in the same age group. Of visits with a primary payer of Medicare, 16 (17.2%) had secondary

167

Medicaid coverage and 60 (64.5%) had private insurance.

168
169

State Ambulatory Surgery and Services Databases

170

In SASD, there were 86 nocardiosis-associated surgical or ambulatory visits identified from

171

14 states in 2015, 471 from 15 states in 2016, and 254 from seven states in 2017 for 811 visits.

172

The nocardiosis-associated visit rate was 0.38/100,000 population.

50

173

Visit counts were similar by sex except among persons younger than 35, of which females

174

accounted for 52 of 71 (73.2%) visits. Among adults 35-64, 45.2% of visits were made by

175

females; in all other age groups, females accounted for close to 50%. Visits had similar

176

breakdown by age groups compared to SID (Table 3.1); a majority of visits occurred among

177

adults between 50 and 74 years old. Regionally, 437 (53.8%) visits were reported in the South,

178

312 (38.4%) were out of the Midwest, although the populations from both the South and

179

Midwest were predominately represented in SASD (42.9% and 32.0%, respectively). Only 52

180

(6.4%) were reported out of the West despite a population proportion of 16.3%.

181

Rural residence may be associated with different types of exposures compared to urban

182

residence; here, 606 (74.7%) of visits occurred among persons who resided in urban areas.

183

Urban residence was only 63.5% among visits in the Midwest, and 83.1% in the South. Urbanity

184

also varied by type of nocardiosis; 27.5% of visits for pulmonary infections resided in rural

185

areas, and only 17% and 19% of visits for disseminated or cutaneous infections were reported

186

with rural residence.

187

Medicare was the primary payer for 32.6% of visits among persons younger than 65, and an

188

additional 188 (51.5%) had private insurance. Of the visits with Medicare as the primary payer,

189

176 (62.0%) had private insurance as well.

190
191
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193

Table 3.1: Demographic characteristics of all Medicare FFS beneficiaries, Medicare FFS nocardiosis cases, and nocardiosis-associated
visits from the State Inpatient Databases (SID) and State Ambulatory Surgery and Services Databases (SASD)±
All Medicare FFS
Medicare FFS
SID
SASD
Characteristics
(N=38,434,496)
(N=3,167)
(N=1,626)
(N=811)
n (%)

n (%)

n (%)

Rate

NA
NA

71.6 (11.5)
NA

61.6 (17.3)
302 (18.7)

0.12

NA

NA

476 (29.5)

0.61

6,383,276 (16.6)

618 (19.5)

778 (48.2)

65-74

18,307,981 (47.6)

1285 (40.6)

494 (30.6)

1.37

75-84

9,235,317 (24.0)

938 (29.6)

246 (15.2)

1.37

85+

4,507,923 (11.7)

326 (10.3)

97 (6.0)

1.20

1,519 (48.0)

624 (38.4)

0.31

1,648 (52.0)

1,001 (61.6)

0.52

29,759,289 (77.4)

2639 (83.3)

1,149 (76.0)

0.56

Black

3,755,377 (9.8)

244 (7.7)

149 (9.9)

0.34

Asian

1,140,792 (3.0)

64 (2.0)

42 (2.8)

0.26

Hispanic

2,640,205 (6.9)

63 (2.0)

121 (8.0)

0.27

Age (Mean [SD]) *
0-49
50-64
< 65

Female
Male
Race/Ethnicity (190)
White

20,538,791
(53.4)
17,895,705
(46.6)

Rate ratio
(95% CI)
Reference
4.9
(4.25,5.65)

n (%)

Rate

62.0 (16.9)
123 (15.2)

0.11

226 (27.9)

0.52

Rate ratio
(95% CI)
Reference
4.9
(4.0, 6.06)

349 (43.0)
11.06
(9.6,12.75)
11.02
(9.32, 13.02)
9.67
(7.7, 12.14)

11.61
(9.46,14.25)
15.22
(12.17,19.02)
6.19
(4.18,9.18)

246 (30.3)

1.23

163 (20.1)

1.61

30 (3.7)

0.66

Reference

408 (50.3)

0.38

Reference

1.66
(1.5,1.84)

403 (49.7)

0.38

1.02
(0.89,1.17)

593 (87.1)

0.48

65 (9.5)

0.27

11

0.14

-

-

Reference
0.6
(0.5, 0.71)
0.46
(0.34,0.62)
0.48
(0.4,0.58)

Reference
0.57
(0.44,0.73)
0.29
(0.16,0.53)
-

Other
558,460 (1.5)
157 (5.0)
35 (2.3)
Unknown
580,373 (1.5)
±All Medicare FFS beneficiaries (190) Oct 1, 2015 and Dec 31, 2017, Medicare FFS nocardiosis cases: Oct 1, 2015 and March 31, 2018, SID and
SASD: Oct 1, 2015 -Dec 31, 2017; * 11 records missing age in SID, 115 records missing race in SID; - Suppressed counts when cell size <11;

194
52

Characteristics of illness

195
196

Medicare

197

Using the ICD-10-CM codes for nocardiosis, pulmonary nocardiosis (A43.0) was the most

198

frequently listed diagnosis for cases, followed by unspecified nocardiosis (A43.9) (Table 3.2).

199

However, these values do not account for the numerous listings of the nocardiosis diagnosis or

200

symptoms on repeated visits. From 40,205 separate visit records, 50.9% had pulmonary

201

nocardiosis (A43.0), and 43.8% were unspecified nocardiosis (A43.9); 1.8% in each group were

202

also reported along with other ICD-10-CM nocardiosis codes.

203

Applying the definitions for each of the main forms of disease (Table 2.1), disseminated

204

disease was the most frequently identified form of nocardiosis (Table 3.2); 700 of these 1,635

205

cases had evidence of neurologic involvement or deficit. However, all neurologic involvement

206

was classified as disseminated without accounting for primary neurologic nocardiosis. Only 239

207

cases (7.5%) had disease that could not be properly classified by disease type and remain

208

“unspecified nocardiosis”.

209

Evaluation of all listed diagnoses on a record, the most prevalent diagnoses were

210

chronic conditions including hypertension (n=371) and hyperlipidemia (n=244). Lung findings

211

were common and reported in multiple diagnosis codes. Pneumonia (n=222) and pulmonary

212

mycobacterial infection (n=205) were both common findings. Symptoms included cough

213

(n=124) and shortness of breath (n=76). Signs included acute respiratory failure with hypoxia

214

(n=108), pleural effusion (n=79), solitary pulmonary nodule (n=72, and other nonspecific

215

abnormal findings of the lung field (n=166). Neurological signs of infection were only identified

216

by one code for intracranial abscess and granuloma (n= 110), and sepsis was reported 112

217

times.

218

Several potential indicators of severe disease were also reported. These included acute

219

kidney failure (n=205), hypoosmolality and hyponatremia (n=141), hyperkalemia (n=77), and

220

acidosis (n=68). There were few common procedures identified. There were 84 procedures

221

reported that drained various parts of the lung, and the same count for short term mechanical

222

ventilation.
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223

The diseases identified most often were ‘other bacterial diseases’ (ICD-10-CM codes

224

A30-A49). Mycobacterial infections were the most reported in 470 visits, 375 of which were

225

pulmonary mycobacterial infections. Bacterial sepsis was reported for 306 (8.9%), and

226

actinomycosis was not common (n=54). ‘Mycoses’ comprised 428 of the infectious diseases

227

(ICD-10-CM codes B35-B49); aspergillosis was reported in 216 cases and candidiasis in 170.

228

Cytomegalovirus was reported in 92 cases (2.7%), HIV in 35 (1.0%), and Pneumocystosis in only

229

14 (0.4%).

230

On average, each nocardiosis case had 3.7 (SD: 8.9) non-nocardiosis infectious diseases

231

listed, and 23.4% of all nocardiosis-associated visits reported one or more other infectious

232

diseases. Because many cases had more than one visit, the change in infectious diseases listed

233

on the first and the last visit records was evaluated under the assumption that more infectious

234

agents would be listed on the first visit as differential diagnoses; the change was negligibly

235

smaller, with an average negative change of 0.051 (SD: 0.71). On the first visit, only 23.7%

236

(n=752) of cases had one and 8.7% (n=276) had two or more infectious diseases listed. At the

237

final visit, this was reduced slightly to 21.6% (n=683) and 7.8% (n=247), respectively.

238
239
240
241

Table 3.2: Counts of Nocardiosis disease form based on ICD-10-CM A43 and expanded definition
for Medicare FFS nocardiosis cases, and nocardiosis-associated visits from the State Inpatient
Databases (SID) and State Ambulatory Surgery and Services Databases (SASD)±
Medicare FFS (N=3,167)
SID (N=1,626)
SASD (N=811)
n (%)
n (%)
n (%)
Nocardiosis
ICD-10-CM
ICD-10ICD-10-CM
ICD-10ICD-10-CM
ICD-10disease form
A43
CM +^
A43
CM +^
A43
CM +
Not specified
1290 (40.7)
239 (7.5)
222 (13.7)
21 (4.3)
400 (49.3) 304 (37.5)
Other
220 (6.9)
NA
312 (19.2)
NA
41 (5.1)
NA
Cutaneous
187 (5.9)
201 (6.3)
107 (6.6)
61 (3.8)
24 (3.0)
37 (4.6)
Pulmonary
1537 (48.5) 1092 (34.5) 1128 (69.4) 739 (45.5) 357 (44.0) 349 (43.0)
Disseminated
NA
1635 (51.6)
NA
683 (42.0)
NA
100 (12.3)
Neurologic*
NA
700 (22.1)
NA
61 (3.8)
NA
21 (4.6)
± Medicare FFS nocardiosis cases: Oct 1, 2015 and March 31, 2018, SID and SASD: Oct 1, 2015 -Dec 31, 2017;
^ICD-10-CM+= the ICD-10-CM code A43 for nocardiosis plus the additional codes listed in Table 2.1;
*Neurologic nocardiosis include only signs/symptoms not denoting disseminated infection (Table 2.1), it was
not separated from disseminated disease in Medicare;
NA- Not applicable- there is no specific ICD-10-CM code for disseminated or neurologic nocardiosis, and
Other was not used as a valid category when applying additional ICD codes.
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242

There were 296 cases with both pulmonary nocardiosis (A43.0) and pulmonary

243

mycobacterial infection (A31.0) listed on their visit records, which is 27.1% of cases with

244

pulmonary nocardiosis and 78.9% of those with pulmonary mycobacterial infections. Per the

245

definitions to classify diagnosis claims into disease types (Chapter 2), 55.4% of cases were

246

classified with pulmonary infections and 44.5% were classified with disseminated infections.

247
248

State Inpatient Databases

249

Based on the ICD-10-CM codes, pulmonary nocardiosis was the most frequently

250

reported nocardiosis-associated diagnosis. Nocardiosis was the primary diagnosis in 349 visits

251

(21.5%), of which 256 (73.4%) were pulmonary nocardiosis. More than one nocardiosis ICD-10-

252

CM code was used on 128 visits, most of which were pulmonary combined with at least one

253

other nocardiosis code; 82% of these visits, ‘Nocardiosis, other’ was the second code.

254

With the application of the additional definitions accounting for nocardiosis-associated

255

diagnostic codes (with the exception that all neurologic signs were separated from the

256

disseminated definition), pulmonary infection was identified most often, then disseminated

257

infections (Table 3.2). Eye infections were too infrequent to report. Neurologic signs and

258

symptoms were identified in 386 visits (23.7%), although most visits were also classified as

259

disseminated infections. Neurologic nocardiosis occurred at a greater frequency among males

260

than seen in the overall nocardiosis cohort (n=43/61, 70.5%), although the gender difference

261

among neurologic infections was not statistically significant (χ2: 2.12, df=1, p=0.146). People of

262

White race accounted for 488 disseminated infection visits (78.7%) and 518 pulmonary visits

263

(74.3%). Black/African Americans accounted for 58 disseminated infection visits (9.4%) and 70

264

pulmonary visits (10.0%). Pulmonary infections were more frequent compared to disseminated

265

and other forms in the Northeast (50.8% vs 35.4%) and West (49.3% vs 41.0%) regions, whereas

266

in the South and Midwest, disseminated and pulmonary forms occurred at a similar frequency;

267

and the difference in disease type by region was statistically significant (χ2: 18.97, df=6,

268

p=0.0042).

269

Combining the diagnoses into categories using the Clinical Classifications Software (CCS),

270

the most frequent category for all visits was pneumonia (1,217, 74.8%); other pulmonary codes
55

271

were also common: respiratory failure, insufficiency, or arrest (593, 36.5%); and pleurisy,

272

pneumothorax, or pulmonary collapse (303, 18.6%). Septicemia was present in 257 visits

273

(15.8%), while skin and subcutaneous tissue infections were present in 208 (12.8%) visits.

274

Disorders affecting fluid and electrolytes were common (739, 45.5%), along with other

275

disorders of deficiency: anemias (691, 42.5%); nutritional deficiencies (515, 31.7%); and other

276

nutritional, endocrine, and metabolic disorders (538, 33.1%).

277

Of the categorized procedures reported, diagnostic bronchoscopy and biopsy of

278

bronchus were listed for 374 visits (23.0%), followed by respiratory intubation and mechanical

279

ventilation (228, 14.0%). Incision of pleura, thoracentesis, and chest drainage were performed

280

during 154 visits (9.5%), and blood transfusions were performed during 199 visits (12.2%).

281

Of all listed individual diagnoses (n=31,534), almost 89% of visits had ‘Factors

282

influencing health status and health services’ (ICD-10-CM Z00-Z99) accounting for 5,490

283

separate diagnoses. On average, 3.8 diagnoses in this category were reported per visit (SD: 2.2).

284

Long-term current drug therapy was the most common subgroup within this category, of which

285

systemic steroids were listed in 265 visits (16.3%). Other frequently listed diagnoses in this

286

category included history of nicotine dependence (n=471), dependence on supplemental

287

oxygen (n=184); ‘do not resuscitate’ orders were listed for 194 visits.

288

There were 4,112 endocrine system diagnoses listed in 1,404 visits (86%). Disorders of

289

fluid, electrolyte, and acid-base balance (ICD-10-CM code E87) were the most frequent

290

subcategory (n=1,1163 diagnoses). Disorders of endocrine glands, including hypothyroidism and

291

other disorders of the thyroid (n=294), were somewhat frequent, as was malnutrition and other

292

nutritional deficiencies (n=482).

293

Various forms of circulatory diseases were reported in 1,284 visits listing 3,367

294

diagnoses; hypertensive diseases were the most common (n=976 diagnoses), followed by

295

ischemic heart disease (n=466), and atrial fibrillation (n=420). Respiratory diagnoses were

296

reported from 1,193 visits for 2928 separate diagnoses; bacterial pneumonia was reported in

297

342 visits, pleural effusion in 204 visits, and respiratory failure in 540 visits. Kidney disease was

298

reported 1,100 times from 717 visits, of which 484 visits had a diagnosis of acute renal failure.
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299

Fewer diagnoses of disorders that affect the blood, blood-forming organs, and immune

300

mechanism were reported (n=1,737), but these were reported from 1,035 visits. Non-

301

nutritional anemias were the most common (n=826) from 740 separate visits. Neoplasms were

302

reported from 386 visits, of which lymphoma and leukemia were the most common (228 of 517

303

diagnoses). Additionally, 522 skin disease diagnoses were reported from 345 (21.2%) visits, and

304

the majority were infections of the skin (n=231) including cellulitis, acute lymphangitis,

305

cutaneous abscesses, and acute lymphadenitis. Only 44 of the skin disease visits (28.2%) were

306

among patients with listed cutaneous nocardiosis; 71.2% were among patients with

307

disseminated disease, which may indicate hematogenous spread from a cutaneous lesion.

308

There were 1456 non-nocardiosis infectious disease diagnoses that were listed on 922

309

(56.7%) visit records. Mycoses comprised 30% of diagnoses, including aspergillosis (n=145) and

310

Candidiasis (n=207). Mycobacterium infections were uncommonly reported. CMV was listed 62

311

times. Systemic inflammatory response syndrome/sepsis was listed for 156 separate symptom

312

diagnoses and 313 that were under infectious agent diagnoses from 334 visits. By presentation

313

of disease, 68.6% were in patients with disseminated disease and 26.6% were in pulmonary

314

nocardiosis.

315

Various symptoms, signs, and diagnostic findings were reported from 1,091 visits

316

accounting for 2,139 diagnoses. Most symptoms fell into the ICD-10-CM category of “General

317

Symptoms and Signs” (n=735); although there were no prominent symptoms or signs; from

318

these, 101 diagnoses were malaise and fatigue, 69 with cachexia, and 58 with fever.

319
320
321

State Ambulatory Surgery and Services Databases
The most frequently listed ICD-10-CM code was ‘Nocardiosis, not specified’ (A43.9)

322

(Table 3.2), followed by pulmonary nocardiosis (A43.1). Nocardiosis was the primary diagnosis

323

for 365 (45.0%) visits. Pulmonary infections were identified most frequently when applying the

324

definitions in Table 2.1, followed closely by nonspecific nocardiosis. Disseminated infections

325

were only identified from 12.3% of visits, and eye infections were too infrequent to report.

326

Disseminated infection visits occurred more often among males (61% vs 39% in females);

327

almost 60% (n=209) of the pulmonary visits occurred among adults 65 and older, while 52% of
57

328

disseminated and 57% of cutaneous nocardiosis visits occurred among patients under 65 years

329

old. Regionally, 61 (61%) disseminated infection visits occurred in the South.

330

The most frequently listed CCS for all visits was pneumonia (404, 49.8%), then bacterial

331

infection (393, 48.5%). Of all listed individual diagnoses (n=3,575), about 48% of visits had

332

‘Factors influencing health status and health services’ (ICD-10-CM Z00-Z99) accounting for 939

333

separate diagnoses. Most of these diagnoses fell into the category of health history that

334

influences health status. There were few diagnoses listed that could be readily classified into

335

meaningful groups.

336
337
338
339

Characteristics of Visits
Medicare
The types of claim records for the 3,167 cases were: 1,813 cases had 7,755 outpatient

340

visits, 1,404 cases had 2,343 inpatient visits, and 2,707 cases had 30,107 separate carrier

341

records. Of the 2,792 cases with more than one visit or record, the mean number of records per

342

person was 14.3 (SD: 17.2). In- and outpatient visits varied in frequency by sex: females

343

received outpatient care at a greater frequency than inpatient care (55.4% of outpatient visits

344

vs 40.4% of inpatient). Cases in people younger than 65 had a greater percentage that received

345

inpatient care than outpatient care (24.2 vs 17.4%).

346

When looking at the number of visits by disease type, cases with disseminated infection

347

had the greatest number of visits (28,476) for an average of 17.4 encounters per case, and

348

74.6% of these encounters were readmission or encounter within 30 days of a previous visit.

349

Cases with pulmonary infections had 9,333 encounters (mean= 8.5), of which 64.1% were

350

readmission or repeat encounters. Cutaneous cases had 1,350 visits (mean= 6.7 encounters),

351

and unspecified nocardiosis had 1,046 encounters (mean= 4.4 encounters).

352

The average length of stay among inpatient visits was on average four days longer,

353

compared to the average duration of care, which includes total follow up time including both

354

inpatient and outpatient care (Table 3.4).

355

The mean cost per case was $38,890 (SD: $168,134) for a total cost of more than $123

356

million during the study period (Table 3.3). The average cost per visit was low since it included
58

357

outpatient, inpatient, and carrier visits, although with a wide standard deviation. Mean costs

358

per case differed by age group, with the highest among cases less than 65 years old ($65,196

359

[SD: $261,119]) and lowest among those 85 and older ($15,868 [SD: $33,180]); however, the

360

standard deviations were wide, demonstrating a large variation in the amount paid for each

361

case.

362

Table 3.3: Visit characteristics for Medicare FFS nocardiosis cases, SID and SASD
Visit characteristics
Medicare FFS
SID
SASD
Total visit records
40,205
1626
811
Duration of care (Mean days,
8.7 (19.1)
0.82 (5.1)
0.4 (5.0)
SD)±
Length of all inpatient stays†
12.7 (13.5)
12.7 (14.7)
0.4 (3.1)
(Mean days, SD)
Outcome
Died
881 (27.8)
102 (6.3)
0
Time to death, days (Mean,
269.1 (262.0)
20.1 (17.9)
SD)*
Total cost**
$123,164,077 $44,033,097
$2,560,033
$3,063
$35,226
$3,427
Cost/visit (Mean, SD)
($44,836)
($69,202)
($10,032)
±Duration of total follow up from first to last nocardiosis-associated visit, including
outpatient and inpatient visits.
†Duration of hospitalization only
*for SID, this is calculated from length of stay for visits where a death was reported
** SASD, this is total charges due to no cost-to-charge ratio data

363
364

Disseminated infections had the highest average costs ($64,133 [SD: $226,704]);

365

average costs for pulmonary infections ($15,258 [SD: $54,160]) and cutaneous infections

366

($6,096 [SD: $24,108]) were substantially lower with less extreme variation within groups. The

367

costs were larger in each subsequently larger CCI group, with the highest among cases with a

368

CCI score of six or more, but again, there was substantial variation within groups. When

369

evaluated by specific nocardiosis-specific risk factors, cases with HIV ($5,802, SD: $65,937),

370

stem cell transplant ($6,029, SD: $46,658), and solid organ transplant ($3,686, SD: $53842) had

371

higher costs per visit than the overall average per visit.

372
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State Inpatient Databases

374

Most hospitalizations were either emergency (974, 60.0%) or urgent (420, 25.9%), and

375

69.8% were not transfers from another healthcare facility. Length of inpatient stay was similar

376

to Medicare (Table 3.3); since length of stay was skewed, means and medians are both

377

reported in Appendix Table 3.1. Median visit length was shorter for each older age group, and

378

was consecutively longer with more chronic conditions or risk factors, regardless of the co-

379

morbidity measure

380

Costs were calculated for 1,520 visits using the cost to charge ratio for SID. Costs

381

represent the actual costs incurred for services and exclude physician fees, whereas charges are

382

the total amount billed by a hospital. The conversion could not be done for all visits because of

383

missing hospital identifiers in all records from four states in all years (Iowa, Minnesota,

384

Nebraska, and South Carolina) accounting for 166 visits (10.2%), as well as 49 visits (3%) in 2017

385

from Georgia, Mississippi, Washington, and West Virginia.

386

The overall and average costs during the study period is in Table 3.4; the median was

387

$18,813 (IQR: $28,895). The average costs per CCI category (Appendix Table A.2) did not reflect

388

the same pattern as the Medicare data, which showed higher average costs with each

389

increasing CCI category; however, the median costs from SID did follow this pattern. The

390

median costs for visits with disseminated ($26,125, IQR: $43,991) and neurologic nocardiosis

391

($26,751, IQR: $37,995) were more than twice the amount of cutaneous nocardiosis ($10,933,

392

IQR: $13,864). Costs for pulmonary nocardiosis was between these ($16,382, IQR: $21,164.

393

Costs were evaluated for some common risk factor comorbidities; median costs for visits

394

with renal failure listed was higher ($21,335, IQR $32,625]) than those without ($16,478, IQR

395

$24,637), visits with malnutrition also had much higher costs ($29,438, IQR: $45,530) than

396

those without ($16,515, IQR: $24,725), as well as those with history of solid organ transplant

397

($22,058 IQR $36,591) than those without ($17,399 (IQR $26,865).

398

Because SID and SASD data are visit-based, there is not an equivalent analysis of

399

readmissions or person-based versus visit-based characteristics. However, because 14 of the 29

400

participating states provide a variable that links visits together at the patient level, the number

401

of repeated visits by the same person during the same year could be evaluated for 722 (44.4%)
60

402

SID and 133 (16.4%) SASD visits, which are combined for this brief description. These visits

403

represented 549 unique individuals, of which 374 (68.1%) had only a single visit; the average

404

number of visits per person was 1.6 (SD 1.1) with a maximum of 10 visits. Among those with

405

more than one visit, the average time between visits was highly skewed (35 days, SD 69), and

406

the median was 5 days (IQR 35).

407
408
409

State Ambulatory Surgery and Services Databases
The primary reason for the visit was pneumonia (169, 27.8%). While 97.2% of all SASD

410

visits were classified as elective, 46.7% (326) were referred by their clinician. Charges instead of

411

costs were calculated for all nocardiosis-associated SASD visits due to the absence of cost-to-

412

charge ratios. The average charges were similar to Medicare costs despite charges

413

overestimating the true costs (Table 3.3). The overall median charge was $745 per visit (IQR:

414

$2,645); almost 10% of the values were extreme outliers, which is clear in the drastic difference

415

between the mean and the median. Median charges were larger each year, but these were not

416

statistically significantly different ([2015: $337, IQR: $723]; [2016: $655, IQR: $1,951]; [2017:

417

736, IQR: $2,357]; χ2=2.05, df=2, p=0.36). Charges appeared lower with each older age group,

418

with a median of $871 (IQR $2,930) in people under age 65 to $379 (IQR $464) in those 85 and

419

older. The number of chronic conditions measure was more evenly distributed into categories

420

(Figure 1), and thus was selected to evaluate chronic conditions on charges. The median

421

charges were statistically significantly different between the categorized comorbidity counts, in

422

which the median charges showed a positive change in each greater chronic condition category

423

from 0 conditions to 6 or more ([$518, IQR: $1,281], [$1,506, IQR: $5,358], χ2=46.35, df=4,

424

p<0.0001).

425
426
427
428

Risk Factors and Chronic Conditions
Medicare
Several chronic conditions that were investigated were highly prevalent among

429

nocardiosis cases, although counts varied based on the definitions of each comorbidity measure

430

(Table 3.4). For example, experiencing renal disease at any time during Medicare coverage was
61

431

highly prevalent (68%), although dropped by more than half when limiting to reported renal

432

disease in the previous 12 months.

433

Conditions that comprise many nocardiosis case reports (e.g., cystic fibrosis and HIV), as

434

well as cytomegalovirus infection, which has been associated with nocardiosis mortality, are

435

not common among this Medicare population (Table 3.4). Prevalent conditions that cannot

436

easily be discerned as being caused by the acute illness or other underlying conditions included

437

anemia, malnourishment, weight loss, and fluid disorders.

438

Of the cases with history of solid organ transplant (SOT), heart transplants were the

439

most frequently identified (889, 66.2%), followed by kidney (353, 26.3%), liver/pancreas (338,

440

25.2%), and lung (146, 10.9%); these add up to more than 100% because some cases had more

441

than one organ transplant reported. Almost half of kidney transplants occurred in cases

442

younger than 65, which is likely due to Medicare availability to persons suffering from end stage

443

renal disease (195). While only 33.5% of cases with transplant history and 35.7% of kidney

444

transplants were women, other transplanted organs were slightly more common in women

445

than men (lung: 55.5%, heart 61.8%, and liver/pancreas 53.6%).

446

Some chronic conditions were associated with the form of nocardiosis. COPD was

447

significantly greater in cases with pulmonary nocardiosis (62.2%) compared to disseminated

448

(52.8%) and cutaneous disease (20.2%) (χ2=120.9, df=2, p <.0001). Diabetes, which can cause

449

both skin and systemic problems, was greater among both cutaneous and disseminated

450

nocardiosis cases (χ2=30.1, df=2, p <.0001). Systemic conditions that cause immunosuppression,

451

including malignancy, renal disease, and SOT, were greater in cases with disseminated infection

452

compared to pulmonary or cutaneous forms. Malignancy among disseminated infections was

453

24.8% compared to 17.5% in pulmonary cases (χ2=28.5, df=2, p <.0001); renal disease was

454

present in 30.8% of disseminated infections and 23.1% of pulmonary (χ2=22.3, df=2, p <.0001);

455

SOT was present in 45% of disseminated infections and 40.3% of pulmonary (χ2=7.2, df=2, p

456

0.0271).

457
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Table 3.4: Counts of comorbid conditions by comorbidity measure identified for Medicare FFS
nocardiosis cases, and nocardiosis-associated visits from the State Inpatient Databases (SID) ±

Conditions
Congestive heart failure
Peripheral Vascular
Disease
Cerebrovascular Disease
Hypertension
Rheumatologic Disease
COPD
Paralysis
Diabetes
Liver (mild-severe)
Renal disease
Malignancy
Metastatic tumor
HIV
Chronic lung disease
Respirator use
Anemia
Malnutrition
Bowel disease
Hemodialysis
Organ transplant
Stem cell transplant
History of immunosuppression therapy
Cell-mediated
immunosuppression
Chronic steroid use
Ectopic Cushing’s
Cystic fibrosis
CMV
Alcohol abuse
Smoking
Drug abuse
Weight loss
Obesity
Fluid/electrolyte disorder
Other neurologic
conditions
Hypothyroidism
Coagulopathy

Medicare
(N=3,080)
Charlson
n (%)
608 (19.7)
434 (14.1)

Medicare
(N=3,167)
Risk factors
n (%)

SID (N=1626)
Charlson
n (%)
338 (20.8)
101 (6.2)

239 (7.8)

92 (5.7)

248 (8.1)
1,642 (53.3)
47 (1.5)
1,241 (40.3)
178 (5.8)
839 (27.2)
643 (20.9)
117 (3.8)
29 (0.9)

117 (7.2)
721 (44.3)
50 (3.1)
416 (25.6)
123 (7.6)
477 (29.3)
289 (17.8)
58 (3.6)
59 (3.6)

1,431 (45.2)
2,136 (67.5)
1,554 (49.1)
56 (1.8)
2,437 (77)
142 (4.5)
2,369 (74.8)
598 (18.9)
116 (3.7)
389 (12.3)
1,343 (42.5)
95 (3)
121 (3.8)

Risk factors
n (%)

Elixhauser
n (%)
267 (16.4)
93 (5.7)

910 (56.0)
124 (7.6)

477 (29.3)
835 (51.4)
464 (28.5)
64 (3.9)
727 (44.7)
25 (1.5)
615 (37.8)
381 (23.4)
23 (1.4)
80 (4.9)
417 (25.7)
36 (2.2)
0

1,052 (33.2)

161 (9.9)

410 (13.0)
112 (3.5)
261 (8.2)
194 (6.1)
193 (6.1)
769 (24.3)

0
80 (4.9)
59 (3.6)
46 (2.8)
149 (9.2)

74 (4.6)
472 (29.0)
104 (6.4)
437 (26.9)
159 (9.8)
50 (3.1)
14 (0.9)
652 (40.1)
601 (37.0)

45 (2.8)
54 (3.3)
418 (25.7)
102 (6.3)
794 (48.8)
183 (11.3)
274 (16.9)
268 (16.5)
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460

Some chronic conditions were associated with the form of nocardiosis. COPD was

461

significantly greater in cases with pulmonary nocardiosis (62.2%) compared to disseminated

462

(52.8%) and cutaneous disease (20.2%) (χ2=120.9, df=2, p <.0001). Diabetes, which can cause

463

both skin and systemic problems, was greater among both cutaneous and disseminated

464

nocardiosis cases (χ2=30.1, df=2, p <.0001). Systemic conditions that cause immunosuppression,

465

including malignancy, renal disease, and SOT, were greater in cases with disseminated infection

466

compared to pulmonary or cutaneous forms. Malignancy among disseminated infections was

467

24.8% compared to 17.5% in pulmonary cases (χ2=28.5, df=2, p <.0001); renal disease was

468

present in 30.8% of disseminated infections and 23.1% of pulmonary (χ2=22.3, df=2, p <.0001);

469

SOT was present in 45% of disseminated infections and 40.3% of pulmonary (χ2=7.2, df=2, p

470

0.0271).

471

The weighted score or unweighted count of each comorbidity measure was categorized

472

to evaluate these nocardiosis cases by demographics and other covariates. While 70% of cases

473

had a weighted score of three or fewer CCI comorbidities (Figure 3.1), the average score in the

474

highest CCI category of 6+ was 7.9 (SD: 2.1). Meanwhile, the unweighted risk factors, which

475

were identified from nocardiosis case reports in the literature (Appendix Table A.1), had an

476

average count of almost twice the CCI score. Almost 75% of cases had more than three

477

nocardiosis risk factor conditions.

478

Some demographic characteristics vary between the CCI categories. Age appears inverse

479

to CCI score and number of risk factors; a greater proportion of cases younger than 65 have

480

higher CCI scores (χ2=79.7, df=9, p<.0001) (Appendix Table A.2). Females had lower CCI scores;

481

only 22.3% had a score of four or greater, while almost 40% of men did (χ2=136.7, df=3,

482

p<.0001). Race also appears to vary by CCI category; the proportion of cases among

483

Black/African Americans was larger in the two highest CCI categories (χ2=269.5, df=12,

484

p<.0001). 96% of ESRD had four or more nocardiosis risk factors, and also had a greater CCI

485

score (χ2=187.0, df=3, p<.0001), as did those with dual Medicare/Medicaid coverage.

486

More severe forms of nocardiosis occurred in cases with a higher CCI score; cutaneous

487

infections were higher than expected in the lower CCI categories, and disseminated infections

488

were higher in the two highest CCI categories (χ2=52.8, df=9, p<.0001) (Appendix Table A.2).
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489

Disseminated nocardiosis also made up a greater proportion of the cases with more than three

490

risk factors compared to lower categories, accounting for 79.4% of disseminated cases

491

(n=1,298) (χ2=134.7, df=9, p<.0001). Three-quarters of cases with history of transplant had six

492

or more risk factors.

493
494
495

State Inpatient Databases
Hypertension, chronic lung disease, COPD, renal disease, and fluid/electrolyte imbalance

496

were present in almost half or more of visits (Table 3.4). Some conditions in the comorbidity

497

measures that were commonly present in these visits, including coagulopathy, anemia, and

498

weight loss, may be associated with the acute Nocardia infection or truly be an underlying

499

factor. Conditions that are frequently associated with nocardiosis in the literature (i.e., HIV,

500

cystic fibrosis, CMV, alcohol, and drug abuse) were infrequently listed on visits (8, 111, 114,

501

155, 196).

502

Among the visits with history of SOT, specific organ transplant information was not able

503

to be elicited. However, 336 (80.6%) had renal disease and 79 (18.9%) had chronic pulmonary

504

disease, 59 visits reported both conditions. Almost 69% of visits with SOT were among males,

505

and 64.8% of visits occurred in those younger than 65. Most of the infections were either

506

pulmonary (48.2%) or disseminated (38.6%).

507

Two additional comorbidity measures were included in the SID analysis, the HCUP

508

chronic condition indicator (197) and Elixhauser comorbidity index (198). These were included

509

because SID visit data only contains comorbidities during the single visit record and fails to

510

capture comorbidities present during the 12 months or more before onset, as defined by the

511

Charlson Comorbidity Index (171) or the nocardiosis risk factors measure (Appendix Table A.1).

512

The distribution and average scores for each measure are shown in Figure 3.1. The

513

unweighted count of nocardiosis risk factors and the weighted CCI produced lower scores, 66%

514

of visits had fewer than four risk factors, while 70% had a CCI score less than four. The mean

515

number of chronic conditions from the Chronic Condition Indicator Tool was nearly five times

516

larger (Figure 3.1), and 70% of visits reported six or more conditions.
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517

Evaluating demographics by categorized measure, age was variable for each measure.

518

Females had fewer comorbidities than males in all comorbidity measures. The largest

519

difference was identified among the CCI, in which 22% of visits among females reported a CCI

520

score of four or more compared to 35% of visits among men (χ2: 37.6, df=3, p<.0001) (Appendix

521

Table A.2).

522

The categorized measures by disease form also vary by measure. Most visits reporting

523

cutaneous infection have fewer than four conditions using the risk factors, CCI, and Elixhauser

524

measures. Meanwhile, 57% and 68% of reports with disseminated infection have fewer than

525

four conditions among risk factors and CCI measures. Although the number of chronic

526

conditions is heavily skewed to the highest category of six or more conditions, a greater

527

proportion of disseminated infection visits are in this highest category (79%) than pulmonary

528

infection visits (70%) or cutaneous infections (51%). A similar trend was also seen for the count

529

of Elixhauser conditions.

530

The calculated Elixhauser readmission and mortality scores are more useful values than

531

the count of conditions alone for this measure (174). The average estimated readmission score

532

was 28.3 (SD: 17.1), and the Elixhauser mortality score was 13.4 (SD: 11.6). The average

533

readmission score was highest among visits reporting neurologic nocardiosis (31.5, SD: 16.8

534

[Median: 33, IQR: 20), followed by disseminated (30.2, SD: 17.3 [Median: 30, IQR: 24]). The

535

average readmission score for visits with pulmonary infections was 26.7 (SD: 15.9 [Median: 25,

536

IQR: 22]), and the score for cutaneous nocardiosis visits was only 20.9 (SD: 18.6 [Median: 16,

537

IQR: 29]); the estimated readmission was statistically significant by disease form (χ2=34.2, df=4,

538

p<.0001).

539
540
541

State Ambulatory Surgery and Services Databases
The application of various comorbidity measures to the SASD visit records had limited

542

utility since many of the conditions had numbers too low to report. It is unlikely that the

543

patients who were seen on these visits lacked chronic conditions to the extent shown in Figure

544

3.1, but rather is likely indicative of limited reporting of diagnoses on such visits; almost 85% of

545

records had fewer than 10 diagnoses, whereas 50% of SID records had 20 or more diagnoses.
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546

Additionally, Elixhauser was not run on SASD since it is not validated or recommended for use

547

in SASD.

548

Among conditions with sufficient counts, COPD was reported in 133 (16.4%), 85 had a

549

malignancy (10.5%), and 121 had renal disease (14.9%). Among SASD visits with a history of

550

solid organ transplant (n=171, 21.1%), 67.8% were among males, and almost 77% were among

551

individuals younger than 65. Eighty-five (49.7%) visits with transplant history had pulmonary

552

nocardiosis, and 55 (32.2%) were not specified.

553
554
555
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Mean (SD)

^

*

±

^

Percent of cases (Medicare) or visits (SID and SASD)

556
557
558
559
560
561
562

Figure 3.1. Percent of nocardiosis cases or visits with categorized count or score by comorbidity
measure, among Medicare FFS cases, State Inpatient Databases [SID] visits, and State
Ambulatory Surgery and Services Databases [SASD] visits
^ All comorbidity measures are grouped into a single category of ‘0-1’ conditions for Medicare data, SID
data are collapsed into the ‘0-1’ category when the counts are too small to report individually. * The
count of risk factors for SASD in categories 4-5 and 6+ are too small to report separately. ±Elixhauser
comorbidity index is not validated for use in SASD data, so was not run for SASD.
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563
564
565

Predictors of Mortality
Medicare
Of the 3,167 cases, 881 (27.8%) died at any point during the study period, with an

566

overall average time to death of 269.1 days (SD: 262.0) from the first nocardiosis-associated

567

visit, although 19.5% died within 12 months (Figure 3.2). Dual Medicare coverage, Part B

568

coverage, end stage renal disease, and the original reason for entitlement were similar by death

569

status (Table 3.5).

0-30 days
31-60 days
61-90 days

All cases

91-180 days
181-270 days
271 days-1 year
>1 year
0

570
571
572
573
574

5

10

15

20

25

30

Percent died

Figure 3.2: Percentage died at each time point following the first nocardiosis-associated visit
among Medicare FFS nocardiosis cases
Up to 716 cases (22.6%) had their first visit after April 2017 and were censored prior to

575

the 12-month cut off as shown in the Kaplan-Meier survival curves (Figures 3.3-3.5) but may

576

have subsequently died. Among survivors, the average time from the first nocardiosis visit until

577

the last known visit during the study period was 320.5 days (SD: 90.0).

578

Males had a higher frequency of death compared to females (31.9% vs 23.4%), which

579

was also borne out by age groups. Older cases also had a greater frequency of death compared

580

to each younger age group (39.7%, 29.9%, 25.4%), except cases younger than 65 (48.1%).

581

Cases with a greater number of comorbidities also had a higher frequency of mortality;

582

26.2% of all deaths occurred among cases with a CCI score > 6, which only constituted 14.3% of

583

the included cases. In this group, 50.9% of cases died compared to 16.3% of cases with a CCI

584

score < 1, which comprised 39.2% of all cases. Additionally, this group had a greater frequency
69

585

of either being censored or dying within 30 and 60 days of their first visit compared to the other

586

CCI categories (9.0% vs 4.0-5.7%, 7.9% vs. 3.6-5.3%, respectively). Risk factors were evaluated

587

separately from CCI; 75.1% of cases had four or more nocardiosis risk factors, of which 31%

588

died.

589

Deaths occurred more frequently among cases with disseminated disease regardless of

590

the CCI category, although the mortality rate positively changed with each increase in CCI

591

category (22.7%, 35.4%, 37.4%, and 53.8%) which gives an overall mortality of 34.6% among

592

disseminated cases. Mortality among cases with pulmonary disease followed this same pattern

593

(12.3%, 23.5%, 31.0%, and 51.1%) for an overall mortality rate of 23.4%. CCI classification of

594

cases with skin or unspecified disease cannot be reported due to small cell size.

595

Kaplan-Meier survival curves were developed to compare survival over time by

596

nocardiosis disease type, CCI, and risk factor categories. There was a high percentage of

597

censoring in each analysis (70.9%, 72.2%, and 72.2% respectively). There was evidence of a

598

statistically significant difference between the survival curves for nocardiosis disease form (χ2:

599

61.54, degrees of freedom [df]: 2, p<0.0001) (Figure 3.3). The three main disease forms have

600

clearly delineated survival curves. Survival remains at or near 100% until approximately 50 days

601

for cases with skin infections.

602

The survival curves for the categorized CCI scores demonstrate a statistically

603

significantly different all-cause mortality between these groups (χ2: 235.10, df: 3, p<0.0001)

604

(Figure 3.4). The survival probability of cases with a score >6 appears to separate from the

605

other groups around 25 days, and the rest of the categories separate from each other after 50

606

days. Similarly, the survival curves for number of known nocardiosis risk factors (0-1, 2-3, 4-5,

607

and 6+) significantly differ (χ2: 47.44, df=3, p<0.0001), although the visual differences are less

608

distinct compared to the CCI survival curves (Figure 3.5).

609

Average time to death was calculated for CCI separately from the biased Kaplan-Meier

610

estimates. The average was shortest among CCI group 4 (217.9, SD: 213.1), while the next

611

shortest was CCI group 1 (mean 243.0, SD: 260.6), and the longest was CCI group 2 (mean

612

312.2, SD: 281.9).

613
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Figure 3.3: Kaplan Meier survival curves of Medicare nocardiosis cases for all-cause mortality by
type of nocardiosis, October 1 2015- March 31, 2018; logrank testing for homogeneity between
curves, n=3167

Figure 3.4: Kaplan Meier survival curves of Medicare nocardiosis cases for all-cause mortality by
Charlson Comorbidity Index score, October 1 2015- March 31, 2018; logrank testing for
homogeneity between curves, n=3167
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Risk Factor Count

635
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Figure 3.5: Kaplan Meier survival curves of Medicare nocardiosis cases for all-cause mortality by
number of risk factors, October 1, 2015- March 31, 2018; logrank testing for homogeneity
between curves, n=3167
In the adjusted Cox regression model of nocardiosis cases, age had a small impact with a

641

2% increase in mortality rate for each additional year of age, while females had a 19% lower

642

mortality rate than men (Table 3.5). Cases with higher CCI scores had a higher adjusted

643

mortality rate; cases with a CCI score of 2-3 had a 78% higher mortality rate compared to those

644

with a score <1, while this increased to two to almost four times the mortality rate for cases

645

with CCI score of 4-5 and >6, respectively. Both pulmonary and disseminated infections were

646

also associated with a higher adjusted mortality rate compared to cases with only “not

647

specified” nocardiosis.

648
649

72

650
651

Table 3.5: Descriptive characteristics and adjusted Cox proportional hazards model of Medicare
FFS nocardiosis cases between Oct 1, 2015 and March 31, 2018, by death or censoring status
Descriptive Statistics
Adjusted Cox proportional
hazards model
Variables
Died
Censored or alive
HR (95% CI)
p value
n=881
n=2286
n (%)
n (%)
Female
355 (40.3)
1164 (50.9)
0.81 (0.70, 0.93) 0.0026
Male
526 (59.7)
1122 (49.1)
Age (mean, SD)
72.1 (11.7)
70.4 (11.4)
1.02 (1.01, 1.03) <0.0001
No Part B coverage
17 (1.9)
25 (1.1)
2.07 (1.28, 3.35) 0.0027
ESRD
89 (10.1)
211 (9.2)
0.85 (0.67, 1.08)
0.17
Original reason for entitlement
OASI
586 (66.5)
1552 (67.9)
DIB
237 (26.9)
514 (22.5)
ESRD
30 (3.4)
103 (4.5)
DIB/ESRD
28 (3.2)
117 (5.1)
Dual coverage
182 (20.7)
418 (18.3)
CCI weighted score (mean,
4.1 (3.0)
2.5 (2.3)
SD)
0-1
202 (22.9)
1038 (45.4)
Reference
2-3
262 (29.7)
668 (29.2)
1.78 (1.48, 2.14) <0.0001
4-5
186 (21.1)
357 (15.6)
2.26 (1.84, 2.77) <0.0001
6+
231 (26.2)
223 (9.8)
3.72 (3.06, 4.53) <0.0001
Risk factors (mean, SD)
5.2 (2.4)
5.2 (2.4)
0-1
22 (2.5)
132 (5.8)
2-3
112 (12.7)
523 (22.9)
4-5
274 (31.1)
734 (32.1)
6+
473 (53.7)
897 (39.2)
Nocardiosis disease form
Not specified
30 (3.4)
209 (9.1)
Reference
Cutaneous
31 (3.5)
170 (7.4)
1.24 (0.75, 2.06)
0.39
Pulmonary
255 (28.9)
837 (36.6)
2.05 (1.40, 2.99) 0.0002
Disseminated
565 (64.1)
1070 (46.8)
2.99 (2.07, 4.32) <0.0001
Abbreviations: SD=Standard Deviation, ESRD=end stage renal disease, OASI=old-age and
survivor’s insurance, DIB=disability insurance benefit, CCI=Charlson comorbidity index,
HR=hazard rate; CI= confidence interval

652
653
654
655

State Inpatient Databases and State Ambulatory Surgery Databases
Inpatient visit outcomes were captured by disposition of the patient. While 39.7% were
routine discharges, 29% were discharged to some other facility, including short term care
73

656

facilities. An additional 24.3% were transferred to receive home health care, and 102 (6.3%)

657

died during the hospitalization. Little outcome information was available for surgical and

658

ambulatory visits: 789 (99.3%) visits were listed as routine discharge, and the disposition for 16

659

visits was missing. No deaths were reported from these visits.

660

Disseminated nocardiosis visits had the highest average Elixhauser mortality score (15.2,

661

SD: 11.7 [Median: 14, IQR: 29), followed by visits with neurologic infection (15.1, SD: 13.2

662

[Median: 14, IQR: 18). Cutaneous infection visits had the lowest mortality score (7.3, SD: 11.2

663

[Median: 6, IQR: 13). The differences in median ranks also differed significantly (χ 2=57.2, df=4,

664

p<.0001).

665

Looking specifically at patients using the ‘visitlink’ variable, 66% of repeated visits were

666

among males. There were 54 deaths among 549 unique individuals for a mortality rate of 9.8%.

667

Visits with disseminated infections had the highest mortality at 10.8% (n=74/683), while

668

pulmonary infections had a mortality rate of 3.4% (n=25/737); the mortality for the other

669

groups was too small to report. Length of stay was longer among visits where death was

670

reported (Appendix Table A.2). Mortality rates were lowest in the category with the fewest

671

comorbidities in each of the comorbidity measures, in which they ranged from 0-4%, and were

672

larger in each subsequent category; in the category of >6, the range of mortality rates were 7.7-

673

12.2%.

674
675

Comparison of comorbidity measures as predictors of in-hospital mortality and predictor of

676

mortality

677

None of the comorbidity measure pairs suffers from collinearity (Appendix Table A.4). A

678

baseline model was first selected to include demographic variables that are potential

679

confounders; although two potential confounders, race and urban residence, did not affect

680

other potential confounders and were excluded from the baseline model. Region and median

681

income were also excluded due to affecting the Global Score test of the model. Each

682

comorbidity measure was added to the baseline model, and the AIC and c-statistics are

683

reported for each model in Appendix Table A.5. The Elixhauser mortality score provided the

684

most predictive model of the four measures; surprisingly, the weighted Charlson Comorbidity
74

685

Index measure performed worse than the non-weighted measures of known nocardiosis risk

686

factors and the number of chronic conditions (Appendix Table A.5).

687

On bivariate analysis, chronic steroid use, reliance on a respirator, and CMV infection

688

were statistically significantly associated with death, but the cell sizes were <10 and thus were

689

not included in the multivariable model. All variables in that were included in the initial model

690

were retained for the highest AIC and c-statistic.

691
692
693

Table 3.6: Crude and Adjusted Odds Ratios (OR) from a Multivariable Logistic Regression Model
on the Outcome of Death During a Nocardiosis-Associated Hospitalization Using SID
Died during hospitalization
Variable^

Crude OR
(95% CI)
Reference

p-value

Adjusted OR
(95% CI)
Reference

p-value

Male

N (%)
(n=102)
56 (54.5)

Female

46 (45.1)

1.34
(0.90, 2.01)

0.1549

1.57
(1.02, 2.41)

0.0387

Age
0-64
65-75

35 (34.3)
34 (33.3)

75+

33 (32.4)

Reference
1.6
(0.98, 2.6)
2.3
(1.4, 3.8)

Length of Stay
Above median
Below median=8

0.8294
0.0063

Reference
1.50
(0.90, 2.51)
2.13
(1.26, 3.58)

0.8999
0.0184

76 (74.5)
26 (25.5)

Reference
Reference
2.6
<.0001
1.53
0.096
(1.7, 4.1)
(0.93, 2.52)
Disseminated
74 (72.6)
3.96
<.0001
3.06
<.0001
nocardiosis*
(2.53, 6.19)
(1.92, 4.90)
Elixhauser
102 (100)
1.06
<.0001
1.03
0.0019
Mortality score
(1.04, 1.08)
(1.01, 1.06)
Cerebrovascular
17 (16.7)
3.86
<.0001
2.31
0.0074
disease *
(2.18, 6.82)
(1.25, 4.27)
Malignancy*
41 (40.2)
1.75
0.0079
1.41
0.13
(1.16, 2.64)
(0.91, 2.2)
Malnutrition*
44 (43.1)
2.668
<.0001
1.52
0.091
(1.77, 4.02)
(0.94, 2.46)
^Final model AIC: 680.709, Hosmer-Lemeshow Goodness of Fit: χ2= 11.5, df=8, p= 0.17
*Reference is absence of risk factor or of disseminated disease
694
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695

The final multivariable model estimated the odds of death among visits with

696

disseminated nocardiosis to be three times greater than the odds among visits reporting other

697

forms of nocardiosis, when controlling for demographics, length of stay, and comorbid

698

conditions (Table 3.6). Similarly, visits in which cerebrovascular disease (CVD) was reported also

699

had a 2.3 times greater odds of death compared to those visits without CVD, controlling for

700

factors in Table 3.6. For each additional point of the Elixhauser comorbid score, there is a 3%

701

positive change in the odds of death, when controlling for other factors.

702
703
704
705

State Aggregated Characteristics
Medicare and State Inpatient Databases
Four states contributed 34.5% of all nocardiosis cases from Medicare, which were

706

Arizona, California, Florida, and Texas, although these states comprised 24% of the Medicare

707

population during the study time. Arizona had the highest incidence rate (14.1/100,000 person

708

years), which was 2.4 times larger than the next highest state rate (Montana: 5.9/100,000

709

person years). The median incidence rate per state was 3.2 (IQR 1.5). There were nine states

710

with rates greater than 4.2/100,000 (Figure 3.6A).

711

In SID, three states contributed 44.9% of nocardiosis-associated hospitalizations

712

(Arizona, Florida, and Minnesota), but only comprised 20% of the study population. Arizona had

713

the highest hospitalization rate in SID as well (2.1 hospitalizations per 100,000 person years),

714

which was almost two times larger than the next highest calculated rate in Washington DC (1.1

715

hospitalizations per 100,000 person years). The median hospitalization rate from the

716

participating states was 0.31 per 100,000 person years (IQR 0.25), and six states have rates

717

greater than the median (Figure 3.6B). From both data sources, Arizona, Iowa, Florida,

718

Minnesota, and New Mexico each had incidence and hospitalization rates in the upper

719

quartiles, and the Arizona rates were both extreme outliers of the respective distributions.

720

The Nocardia spp. reference laboratories are shown on the maps in Figure 3.6. In

721

theory, the presence of such expertise could drive additional recognition or diagnosis of

722

nocardiosis; however, this does not appear to be an impact in any state other than Arizona, in

723

which case there is likely another explanation.
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Figure 3.6. (A) Nocardiosis incidence per 100,000 person years calculated from 100% FFS
Medicare data, Oct 2015-March 2018; (B) Nocardiosis hospitalization rate per 100,000 person
years calculated for 26 states in SID, Oct 2015-December 2017
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Chapter 4: Discussion
I.

Discussion of findings

Evaluating nocardiosis cases using population-level data provides a description of the

732

disease that can be generalized to a broad population in the US, constituting all Medicare FFS

733

beneficiaries and all residents of 29 states, or 47% of the US population (167). The

734

comprehensive literature review will serve as a large component of an invited review of the

735

disease, the last of which was published in 2006 (6).

736

The results from this work will contribute to the existing literature to replace existing

737

incidence and mortality estimates, which have been limited in scope (13) or dated (1, 48).

738

These findings will serve as a baseline from which to build additional research studies, and has

739

identified locations in which to target activities, such as Arizona. The use of administrative

740

discharge data, particularly the longitudinal Medicare data, allowed for an evaluation of

741

preexisting conditions, the extent of healthcare use, and the time to death.

742

This comprehensive description of case characteristics has found that cases are more

743

often male, older, and sicker. The male to female ratio is 87:100 in Medicare FFS (190), but 108

744

per 100 females among nocardiosis cases. The same trend is found among nocardiosis visits

745

(160 males/100 females) compared to the US population (97 males/100 females) (199).

746

Medicare cases are slightly younger than the full Medicare population, while the nocardiosis-

747

associated visits in SID are among patients much older than the estimated median age of the US

748

population of 37.8 ± 0.1 and with a greater proportion covered by Medicare (63%) than the

749

population (18.1% ± 0.1) (199). In Medicare data, 60.7% of all ESRD prevalent cases in 2016

750

were covered by primary payer FFS Medicare (200), and enrollments for disability and ESRD are

751

higher among the nocardiosis cases.

752

Duration of hospitalization and costs were higher for nocardiosis cases and nocardiosis-

753

associated visits than the national average, indicating nocardiosis cases require extensive and

754

lengthy care and support. The average length of stay among all US adults was 4.6 days and

755

increased to 5.1 days in adults over age 45 (201); the average length was almost three times

756

this duration in both Medicare and SID data. The average hospitalization cost in SID was
78

757

$35,226, which was three times greater than the national average cost per hospitalization

758

$11,700 (201).

759

For the most part, these findings are consistent with the existing literature, although a

760

wider gap by sex was found among nocardiosis visits of all ages in SID compared to Medicare.

761

Additionally, beneficiaries who were older, were male, or never had Part B Medicare coverage

762

had a greater hazard of dying. Females were associated with a lower hazard of dying, which

763

may indicate less severe disease. Case series disproportionately report disease occurrence

764

among males, with ratios ranging from 2-3: 1 (65, 109). However, in laboratory and facility

765

surveillance studies, this difference is less extreme (5). Males receive a greater proportion of

766

transplants (109) and have greater incidence of most cancers (202), both of which are

767

important risk factors for nocardiosis and poor outcomes (13, 129). Consequently, males may

768

have more severe nocardiosis, may have more repeat visits, and subsequently greater

769

mortality. Additionally, because of worse outcomes, they may be more likely to be recognized

770

and published in the literature.

771

Medicare beneficiaries younger than 65 are more likely to have lower income, poorer

772

health, and have limited access to care compared to beneficiaries 65 and older (203). Never

773

having Medicare Part B outpatient coverage is an indicator of low income, since Part B coverage

774

is an additional cost (204). Lower income is associated with higher mortality, particularly among

775

preventable conditions (205), and nocardiosis occurs less often in healthy individuals (6).

776

Limited access may delay diagnosis, which along with poor health can lead to poorer outcomes

777

from nocardiosis (4).

778

Disseminated nocardiosis and greater number of co-morbidities were associated with a

779

lower survival and had a greater hazard of dying. The drop in survival among beneficiaries with

780

skin infections may indicate dissemination or complications of disease that we were unable to

781

capture in the coding. Mortality does occur infrequently among cutaneous nocardiosis, but is

782

typically associated with an underlying condition (53) or subsequent dissemination (42). Higher

783

mortality among both pulmonary and disseminated infections is supported in the nocardiosis

784

literature (5, 42). In future, a comparison to matched controls could determine if there are

79

785

important differences in nocardiosis cases and controls. Such differences may be useful to raise

786

the clinical specter for opportunistic infections, including nocardiosis-like illness.

787

Higher scores on the Charlson Co-morbidity index have been linked to poorer outcomes

788

and higher mortality (206, 207), which are consistent with our findings. The score is weighted to

789

account for greater debilitation from certain conditions, including malignancies and liver

790

disease (171). The less distinct drop in survival among the nocardiosis risk factor categories

791

compared to the CCI categories is likely due to a lack of weighting on the risk factors. This

792

demonstrates that the weights applied in the CCI may predict mortality. This finding was not

793

borne out in the SID analysis, as the CCI was found to be the worst performing comorbidity

794

measure to estimate mortality, and may be the limitation of the CCI in visit-based analysis

795

without capturing conditions that are present in the past year. The Elixhauser measure should

796

be selected or at least evaluated in future analyses of nocardiosis cases.

797

The incidence and mortality estimates are more robust given the current aging

798

population (19). The existing incidence rate was calculated by Beaman in 1976 based on a

799

survey with low response rate (1); although he described the limitations of this estimate of

800

1,000 incident cases per year, the number nevertheless has since been reported and referenced

801

repeatedly as the national incidence of nocardiosis. Beaman’s count gives an incidence rate of

802

0.47/100,000 (208). The incidence in the Medicare population alone is seven times this

803

estimate, which is a more accurate estimate to use. To reference the US population instead, the

804

SID hospitalization rate of 1.02/100,000 population is still more accurate.

805

Evaluating nocardiosis rates at the state level may suggest the influence of

806

environmental factors (e.g., dust storms or soil composition that is preferred by more virulent

807

Nocardia species), population factors (e.g., older population), or behavioral factors (e.g., more

808

soil exposure) based on geography. These findings could also be an artifact due to disease

809

awareness by clinicians in certain areas, such as areas where there is a clinical laboratory expert

810

or reference laboratory. However, Arizona is the only state with an elevated rate and the

811

presence of a reference laboratory with a Nocardia spp. focus, which dispels this myth.

812

Additionally, reference laboratories that publish summaries of their data receive samples from

813

a majority of US states, so their influence extends beyond their state borders (2, 17). Of course,
80

814

the geographic location of a hospitalization does not indicate where the exposure occurred,

815

and thus other data are needed to investigate any geographic influence on nocardiosis.

816

II. Addressing the Study Design Approach

817

Although the Medicare and HCUP analyses are separate, and despite a majority of

818

Medicare beneficiaries among the HCUP nocardiosis-associated visits, both data sources add to

819

the story of nocardiosis in the US by capturing both older adults and a population of younger

820

adults who are also at risk of nocardiosis. However, the downside of using HCUP is the inability

821

to apply the comorbidity measures over time, and thus likely underestimate the prevalence of

822

some comorbid conditions. This could affect the selection of the Elixhauser comorbidity

823

measure over the other measures as well as the mortality estimates.

824

III. Limitations

825

A major limitation to these analyses is that these are administrative discharge records,

826

and do not indicate a laboratory confirmation. The sensitivity of discharge records has not been

827

evaluated for nocardiosis, nor can that be done given these data. This is especially a concern in

828

using ICD-10-CM codes for a disease that did not have an individual code in ICD-9-CM (9);

829

however, the benefit to using a new code as a crosswalk was not needed between the two

830

coding systems. However, crosswalk coding was needed to apply ICD-9-CM and unvalidated

831

ICD-10-CM codes to collect the comorbid conditions (171, 175, 176, 209-221). Promising

832

findings from a study done among medical coders found that a majority felt minimum training

833

would be needed to transition to ICD-10-CM, and that the instructions and clinical descriptions

834

were clearer than ICD-9-CM (222); these results are promising that the beta versions of these

835

codes will not change drastically to be validated.

836

The application of ICD-10-CM coding to define the form of nocardiosis disease is not

837

validated, and the high number of disseminated infections could be due to medical coding

838

errors (e.g., listing various A43.X codes for a patient with only a single form), which could cause

839

misclassification error.

840

Medians cannot be reported per data use requirements to use the CCW. This allows for

841

extreme values to affect the estimated measures of central tendency, which was evident

842

among many of the covariates evaluated by the large standard deviations. This limits the results
81

843

of the survival analysis by underestimating the means of the Kaplan-Meier curves due to high

844

level of censoring and are thus not reported here. Median estimates were not allowed to be

845

outputted for the survival curves because of the data use agreement restrictions, so median

846

times can only be made by visual inspection of the survival curves.

847

One-year all-cause mortality is limited to beneficiaries who did not change coverage to

848

Medicare Advantage and for whom date of death was appropriately captured. Additionally,

849

beneficiaries who had their first nocardiosis-associated visit <12 months before March 30,

850

2018, may be incorrectly censored if they died after the end of the study period but within one

851

year of their first visit.

852

Additional limitations with the survival analysis additionally include lack of comparison of

853

these findings to a control group, which does not allow comparisons against the rest of the

854

Medicare population. Similarly, no control group was developed for the HCUP data since it is

855

visit-based and thus a control group may not be mutually exclusive from the nocardiosis-

856

associated visit group. A control that is appropriately matched to reduce bias and is of ample

857

sample size should be applied in future.

858

IV. Strengths and Weaknesses

859

Loss of data access early on in the dissertation process led to several weaknesses of this

860

product. The lack of a control group for the Medicare survival analysis weakens the findings of

861

the survival analysis and fails to give the findings context. A control group was developed, but

862

there was a critical error in the code that could not be fixed due to loss of data access,

863

rendering the comparison unpresentable. Loss of data access was a common theme with the

864

Medicare data, which was substantially more robust than the HCUP data.

865

A strength of the work is that these are large datasets compared to the existing

866

literature, and results can be generalized to those beyond the walls of a hospital, which will add

867

to the nocardiosis literature. The databases are complex, particularly the Medicare data, and

868

required merging of many datasets that changed definitions and data structure over time. This

869

work provides a template for using administrative data (aka “Big Data”) containing 100% of

870

records for public health research on rare conditions.

82

871

Other mechanisms to understand a disease may not exist for some rare conditions, such

872

as national surveillance systems, registries, or surveys. Also, easier to access sample data, such

873

as the 5% Medicare FFS databases, may not have sufficient sample size from which to conduct

874

meaningful analyses of rare conditions. Although a highly sensitive and representative case-

875

based surveillance program with data on individual characteristics would be the ideal source

876

from which to describe nocardiosis and predict poor outcomes; however, that level of detail

877

will likely never be available. Utilizing robust administrative data may be the best data source

878

available at this time for a rare disease like nocardiosis, despite their complexity, challenges

879

with access, and for HCUP, the limited answers the data can provide for a disease that requires

880

extended care.

881

V. Public Health Impact

882

This is the largest survival analysis of nocardiosis cases. The data are from a population-

883

level, longitudinal data source, which reduces biases that can be present in facility or

884

surveillance-based analyses. The findings may provide clarity regarding characteristics that

885

place patients with nocardiosis at greater risk of mortality. The findings from the Medicare data

886

are generalizable to the entire Medicare FFS population, while the HCUP data are generalizable

887

to the entire population of the participating states, which constitutes almost 50% of the US

888

population. These findings may assist with identifying infections in patients who present with

889

the identified risk factors and may provide additional insight into which patients have a greater

890

odds of dying.

891

VI. Future Directions

892

Building off this work in the future, the sensitivity of the nocardiosis ICD-10-CM code

893

should be validated against hospitalization records of known nocardiosis cases. If found to be

894

sufficiently sensitive, these data should be re-analyzed over time to evaluate trends,

895

particularly as the population grows older and sicker (19, 20, 127, 160). It might be possible to

896

evaluate the impact of ICD-10-CM implementation, since the presented analyses included data

897

from the first date of the conversion from 9 to 10. The comorbidity measures may also be

898

affected, and hopefully will be validated in the coming years.
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899

Future re-analysis of these data will be of interest to evaluate the effect of the

900

coronavirus (COVID-19) pandemic on nocardiosis as well as other opportunistic infections. The

901

same people may be at risk for both diseases, since older adults and people with underlying

902

conditions are associated with severe coronavirus disease and death (223, 224), and many of

903

these conditions overlap with nocardiosis risk factors (225), including solid organ transplant

904

(224), cancer (226), chronic kidney disease (227), and COPD (228). Transmission mitigation

905

measures implemented for COVID-19 would not prevent exposure to the soil-borne pathogen

906

Nocardia spp. (6); however, the enormous burden of COVID-19 in older and sicker people may

907

decrease the incidence of nocardiosis over the duration of the pandemic.

908

States with highest incidence and hospitalization rates can be targeted for future

909

research activities. These activities may include studies to understand why there are more cases

910

in those states, or even if there are more cases. The latter may be done by developing

911

partnerships with laboratories in these states to compare clinical diagnoses with laboratory

912

diagnoses. Studies in these states may also be able to identify specific populations for which

913

focused messaging on early healthcare seeking may prevent severe outcomes.

914

It was not possible to evaluate the geospatial impact of nocardiosis from these data due

915

to lack of granularity. The development of a dataset with greater geographic granularity of

916

cases and environmental sampling locations may add to the understanding of the pathogen and

917

the disease. Disease severity may be affected by the infecting Nocardia species, and one study

918

suggests that species have variable environmental preferences (41), thus investigating the

919

environmental and climatic characteristics may provide predictions of more severe disease by

920

geography.

921
922
923

VII. Conclusion
The use of administrative data has offered an opportunity to provide generalizable

924

results on a rare disease. Nocardiosis cases were found to be more often male, older, and sicker

925

than the general Medicare and overall US populations, which is consistent with the literature.

926

Infections also require longer care and greater cost, on average, than the US population. The

927

calculated incidence rate was much larger than has previously been reported, and accounts for
84

928

the changes in the US population and advances in medical care over the last 45 years. Mortality

929

was associated with disseminated nocardiosis, cerebrovascular disease, and the presence of

930

additional comorbid conditions, when controlling for other demographic and comorbid factors.

931

Higher mortality among Medicare nocardiosis cases was associated with being older, male,

932

having disseminated nocardiosis, and having a greater number of co-morbidities.

933

These findings will contribute to the nocardiosis literature, and future studies can be

934

developed to further add to these findings or to help explain them. Yet, the difficulty with

935

access and the high cost of the 100% Medicare data are limitations in their use for public health

936

research, particularly when the data collection is federally funded, as were these analyses.

937
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Table A.1: ICD-10-CM and ICD-9-CM codes used to identify risk factors from the diagnosis and procedure variables within each claim
or visit
CCW ±
Reference
Risk
Chronic
Factor/ Name
ICD 10-CM˄
ICD 9-CM ˄
Weight
Conditions
Presence Code
CCI*
§
RF
Cystic fibrosis
E00,E84,E7119,E7141,E7420,E 243,270,2711,2770,2776,25 Oth: Cystic 1
(164)
(216)
7421,E7429,D81810,D841,E03 52,2692,27781,27785, and
fibrosis
0,E031,E250,E258,E259,E569,E CCW codes
700,E701,E702,E703,E705,E70
8,E709,E710, E7111, E712,
E713, E721,E722, E723,
E724,E725,E728, and CCW
codes
RF
Anemia
D59.0 - D59.1, and CCW codes 283, and CCW codes
CC: Anemia 1
(229, 230) (220)
RF

Alcohol abuse

T51,F10, and CCW codes

3050,303,980, and CCW
codes

RF

Immuno-modulated
inflammatory bowel
disease
Bronchiectasis

K50, K51

555, 556

J47,Q334

494.0,494.1, 494,
748.61,V12.69
135,2662, 2730,2731, 2732,
2772, 2776, 2791, 2792,
2793, 2794, 2798,
2799,27906, 28989

RF
RF

Cell mediated immune D81-D89
suppression

Oth:
1
Alcohol use
disorders
1

(196)

(221)

(231)

1

(28)

1

(48)

(28,
209)

99

RF

RF

RF
RF
RF

RF
RF
RF

RF
RF

Personal history of
immuno-suppression
therapy
Long term (current)
use of systemic
steroids
Cytomegaloviral
disease
Ectopic Cushing’s
Chronic
granulomatous
disease
Dependence on renal
dialysis, and history of
Dependence on
respirator
Smoking

Z92.25

V87.46

1

(8, 11)

Z79.52

V58.65

1

(63)

B25

78.5

1

(11)

E24.3
D71

255
288.1

1
1

(232)
(233)

Z99.2, Z92.89

V45.11, V15.89

1

(129, 234)

Z99.1

V46.1

1

(235)

T65,F17, and CCW codes

3051,98984,V1582, and
CCW codes

1

(65)

(215)

Malnutrition
Solid organ transplant,
hematopoietic stem
cell transplant, history
of

E40-E46
Z94,T86,D898,07Y,0BY,0DY,0F
Y,02Y,0TY,0UY,0WY,BT29,BT39
,BT49

260 - 263, 269
E8780, 9968,V5844,
V42,4194, 0794, 335,336,
697,3751,556, 528,
505,2795,9968, 4697,

1
1

(236)
(8, 11)

(237)

1

(65)

Oth:
Tobacco
use

6592,

RF

Chronic lung disease,
Pulmonary alveolar
proteinosis, Other
interstitial pulmonary
disease

J8401,I278, I279, J684, J701,
J703,J40,J41,J42,J43,J44,J45,J4
6,J47,J60,J61,J62,J63,J64,J65,J
66, J67, and CCW codes

4168,4169, 5064, 5081,
5088,90,491,492,493,494,4
95,496,497,498,499,500,50
1,502,503,504,505,516, and
CCW codes

CC: COPD

(8, 171,
172,
209)

100

CCI
RF

Chronic pulmonary
disease
Chronic kidney
disease

I27.8, I27.9, J40.x-J47.x, J60.xJ67.x,J68.4, J70.1, J70.3
N08,N16,N19,N00,N20,N30,N
40,N050,N060,N070,B520,C64
1,C642,C649,C689,D593,E748,I
120,I129,I130,I132,I701,I722,K
767,N011N019,N131,N132,N140-N144,
N150,N158,N159,N170,N171,
N172,N178,N179,N181-N186,
N189,
N250,N251,N259,N261,N269,
Q612,Q613,Q614,Q615,Q618,
Q620,Q622,R944,A1811,A527
5,D3000,D3001,D3002,D4100,
D4101,D4102,D4110,D4111,D
4112,D4120,D4121,D4122,E08
21,E0822,E0829,E0865,E0921,
E0922,E0929,E1021,E1022,E10
29,E1065,E1121,E1122,E1129,
E1165,E1321,E1322,E1329,I13
10,I1311,M1030,M1038,M103
9,M3214,M3215,M3504,N133
0,N1339,N2581,N2589,Q6102,
Q6111,Q6119,Q6210,Q6211,Q
6212,Q6231,Q6232,Q6239,M1
0311,M10312,M10319,M1032
1,M10322,M10329,M10331,M
10332,M10339,M10341,M103
42,M10349,M10351,M10352,
M10359,M10361,M10362,M1

416.8, 416.9, 490.x-505.x,
506.4, 508.1, 508.8, 519.1
189,223,580,581,582,583,5
84,585,586,587,588,591,95
4,,0160,1899,2494,2504,27
14,2741,4401,4421,5724,58
04,5809,7532,7944,,23691,
28311,40301,40311,40391,
40402,40403,40412,40413,
40492,40493,58081,58089,
75312,75313,75314,75315,
75316,75317,75319,75321,
75322,75323,75329, and
CCW codes

1
CC: chronic
kidney
disease, if
ESRD=Yes

1

(171)
(47)

(219)

101

0369,M10371,M10372,M1037
9, and CCW codes
I12.0, I13.1, N03.2-N03.7,
N05.2-N05.7, N18.x, N19.x,
N25.0,Z49.0-Z49.2, Z94.0,
Z99.2

CCI

Renal disease

RF

Hematopoietic stem
cell transplant
Diabetes mellitus

Z9484

CCI

Diabetes without
chronic complications

CCI

Diabetes with chronic
complications

E10.0, E10.1, E10.6,
E10.8,E10.9, E11.0, E11.1,
E11.6, E11.8, E11.9, E12.0,
E12.1, E12.6, E12.8, E12.9,
E13.0, E13.1, E13.6, E13.8,
E13.9, E14.0, E14.1, E14.6,
E14.8, E14.9
E10.2-E10.5, E10.7, E11.2E11.5, E11.7, E12.2-E12.5,
E12.7,E13.2-E13.5, E13.7,
E14.2-E14.5,E14.7
B20,Z21,B9735, and CCW
codes

RF

RF
HIV/AIDS
CCI

E08-E13, and CCW codes

B20.x-B22.x, B24.x

403.01, 403.11, 403.91,
404.02, 404.03, 404.12,
404.13, 404.92,404.93,
582.x, 583.0-583.7,
585.x,586.x, 588.0, V42.0,
V45.1, V56.x
V4282
249, 250, 357.2,
362.01,362.02,362.03,362.0
4,362.05,362.06,366.41,
and CCW codes
250.0-250.3, 250.8, 250.9

2

CC:
diabetes

250.4-250.7, 362.0

969,970,974,975,976,977,0
7953,042,043,V08, and
CCW codes
042.x-044.x

Oth:
HIV/AIDS

(171)

1

(12)

1

(105)

(217)

1

(171)

2

(171)

1

(29)

(171,
218)

6

102

RF

Malignancy
(neoplasms)

Z85,C00-C26,C30- C34,C37C41,C43,C45-C58,C60C76,C81-C85,C88,C90-C97,
and CCW codes

140-172,193,194,200208,1950-1958,2386,V10,
and CCW codes

CCI

Any malignancy,
including leukemia
and lymphoma

140.x-172.x, 174.x195.8,200.x-208.x, 238.6

2

(171)

CCI

Metastatic solid
tumor
Myocardial infarction
Congestive heart
failure

C00.x-C26.x, C30.x-C34.x,
C37.x-C41.x, C43.x, C45.xC58.x,
C60.x-C76.x, C81.x-C85.x,
C88.x,
C90.x-C97.x
C77.x-C80.x

196.x-199.x

6

(171)

I21.x, I22.x, I25.2
I09.9,I11.0, I13.0, I13.2, I25.5,
I42.0, I42.5-I42.9, I43.x, I50.x,
P29.0

410.x, 412.x
398.91, 402.01, 402.11,
402.91, 404.01, 404.03,
404.11, 404.13, 404.91,
404.93, 425.4-425.9, 428.x
093.0, 437.3, 440.x, 441.x,
443.1-443.9, 447.1, 557.1,
557.9, V43.4
362.34, 430.x-438.x

1
1

(171)
(171)

1

(171)

1

(171)

290.x, 291.1,291.2,292.82,
294.1, 331.0,331.2,331.82
446.5, 710.0-710.4, 714.0714.2, 714.8, 725.x
531.x-534.x
334.1, 342.x, 343.x, 344.0344.6,344.9

1

(171)

1

(171)

1
2

(171)
(171)

CCI
CCI

CCI

Peripheral vascular
disease

CCI

Cerebrovascular
disease
Dementia

CCI
CCI
CCI
CCI

Rheumatologic
disease
Peptic ulcer disease
Hemiplegia or
paraplegia

I70.x, I71.x, I73.1, I73.8, I73.9,
I77.1, I79.0, I79.2, K55.1,
K55.8, K55.9, Z95.8, Z95.9
G45.x, G46.x, H34.0, I60.xI69.x
F00.x-F03.x, F05.1,
G30.x,G31.1
M05.x, M06.x, M31.5, M32.xM34.x, M35.1, M35.3, M36.0
K25.x-K28.x
G04.1, G11.4, G80.1, G80.2,
G81.x,G82.x, G83.0-G83.4,
G83.9

CC:
Cancers

1

(13, 14)

(171,
210214)

103

CCI

Mild liver disease

CCI

Moderate or severe
liver disease

HCUP

End stage renal
disease

B18.x, K70.0-K70.3,
K70.9,K71.3-K71.5, K71.7,
K73.x, K74.x,K76.0, K76.2K76.4, K76.8, K76.9,Z94.4

070.22, 070.23,
070.32,070.33 ,070.44,
070.54, 070.6,070.9, 570.x,
571.x, 573.3, 573.4, 573.8,
573.9, V42.7
I85.0, I85.9, I86.4, I98.2, K70.4, 456.0-456.2, 572.2-572.8
K71.1, K72.1, K72.9, K76.5,
K76.6,K76.7
Z99.2, Z91.15, Z49.31, Z49.32,
(3E1M39Z, 5A1D70Z- 5A1D90Z

1

(171)

3

(171)

* CCI=Charlson comorbidity index
^ If no references are listed for codes, the website ICD10.com was used to search for codes related to the condition. These are likely less robust
compared to those created by the CCW or Charlson Co-morbidity Index ± CCW=Chronic conditions warehouse
§ Cc=CCW chronic conditions
§ Oth= and Other Chronic or Potentially Disabling Conditions
1514
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Table A.2: LOS for inpatient visits for SID
Mean days
Median
Characteristic
(SD)
days (IQR)
Overall
12.7 (14.7)
8 (12)
Age group (years)
0-34
12.9 (11.7)
10 (10)
35-64
14.6 (18.4)
9 (13)
65-74
12.0 (12.5)
8 (12)
75-84
10.6 (10.2)
7.5 (10)
85+
8.9 (9.1)
6 (7)
Sex
Male
13.1 (15.5)
9 (12)
Female
12.1 (13.4)
8 (10)
Race/ethnicity
White
12.3 (14.4)
8 (11)
Black
14.7 (14.4)
11 (12)
Hispanic
11.3 (10.7)
8 (10)
Other‡
15.3 (16.6)
9.5 (16)
Region
Northeast
16.0 (16.4)
11 (14)
Midwest
12.1(15.9)
7 (10)
South
14.2 (16.0)
9 (13)
West
10.8 (10.8)
8 (10)
Type of nocardiosis
Disseminated
16.6 (18.3)
12 (15)
Neurologic
14.2 (13.8)
12 (10)
Pulmonary
10.0 (10.7)
7 (9)
Skin
7.5 (6.8)
6 (7)
Not specified
7.4 (7.6)
5 (7)
Disposition
Discharge alive 12.2 (14.3)
8 (11)
Died
20.1 (17.9)
16.5 (20)
Number Chronic conditions
0
10.9 (10.4)
6 (16.5)
1
9.3 (6.4)
7 (7)
2-3
8.6 (8.2)
6 (9.5)
4-5
9.6 (9.5)
6 (8)
6+
14.0 (16.1)
9 (12)
Charlson CI
0
11.5 (15.7)
7 (12)
1
10.6 (11.7)
7 (11)
2-3
13.4 (15.9)
8.5 (12)
4-5
12.8 (13.7)
8 (13)

Measure of Association †

χ2=17.7, df=4, p=0.0014

χ2=2.05, df=1, p=0.15

χ2=10.5, df=3, p=0.0150

χ2=18.2, df=3, p=0.0004

χ2=132.1, df=4, p<.0001

χ2=26.9, df=1, p<0.0001

χ2=38.5, df=4, p<0.0001

χ2=23.6, df=4, p<0.0001
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6+
15.1 (15.4)
12 (12)
Risk factors
χ2=54.1, df=4, p <0.0001
0
9.2 (8.4)
6 (11)
1
9.8 (11.1)
6 (9)
2-3
12.3 (14.8)
8 (11)
4-5
14.0 (14.7)
10 (13)
6+
20.6 (22.5)
14 (15)
Elixhauser
χ2=95.4, df=3, p<0.0001
0
9. 4 (11.2)
6 (11)
1
9.1 (8.8)
6 (7)
2-3
10.1 (13.3)
6 (9)
4-5
13.5 (15.7)
9 (11)
6+
16.6 (15.8)
12 (16)
† Using the Kruskal-Wallis H-test
‡ ‘Other’ race includes Asian/Pacific Islander, Native American, and Other, and
were combined due to small numbers
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Table A.3: Demographics by Charlson Comorbidity Index for Medicare FFS nocardiosis cases and nocardiosis-associated visits from the
State Inpatient Databases (SID)±
Medicare
SID
CCI weighted score
CCI weighted score
Characteristics
0-1
2-3
4-5
6+
0-1
2-3
4-5
6+
N=1,240
N=930
N=542
N=454
N=510
N=632
N=294
N=190
Age (Mean)
72.7 (10.5)
71.8 (12.0)
69.5 (12.3)
70.4 (11.5)
56.4 (21.5)
64.1 (14.2)
66.5 (12.7)
59.7 (16.2)
< 65
168 (13.6)
183 (19.7)
151 (27.8)
116 (25.6)
282 (55.3)
282 (44.6)
121 (41.2)
104 (54.7)
65-74
561 (45.2)
335 (36.0)
218 (40.2)
171 (37.7)
124 (24.3)
215 (34.0)
103 (35.0)
52 (27.4)
75-84
374 (30.2)
315 (33.9)
123 (22.7)
126 (27.8)
75 (14.7)
103 (16.3)
43 (14.6)
85+
137 (11.1)
97 (10.4)
51 (9.4)
41 (9.0)
29 (5.7)
32 (5.1)
27 (9.2)
Female
728 (58.7)
452 (48.6)
195 (35.9)
144 (31.7)
238 (46.7)
250 (39.6)
90 (30.6)
46 (24.2)
Male
512 (41.3)
478 (51.4)
347 (64.0)
310 (68.3)
272 (53.3)
381 (60.4)
204 (69.4
144 (75.8)
Race
White
1,098 (88.6)
787 (84.6)
403 (74.2)
351 (79.2)
394 (81.4)
455 (77.3)
196 (74.0)
104 (60.1)
Black
39 (3.2)
62 (6.7)
75 (13.8)
68 (15.3)
32(6.6)
47 (8.0)
28 (10.6)
42 (24.3)
Hispanic
0
20 (2.4)
19 (3.5)
24 (5.4)
40(8.3)
51 (8.7)
20 (7.6)
Other
17 (1.4)
61 (6.6)
18 (3.3)
18 (3.7)
36 (6.1)
21 (7.9)
17 (9.8)
Unknown
0
0
28 (5.2)
0
0
0
0
End-stage Renal
88 (9.5)
106 (19.5)
99 (21.8)
NA^
NA^
NA^
NA^
Disease (ESRD)
Insurance
provider
Dual coverage
188 (15.2)
160 (17.2)
134 (24.7)
118 (26.0)
Medicare
NA
NA
NA
NA
250 (49.0)
442 (69.9)
229 (77.9)
109 (57.4)
Medicaid
NA
NA
NA
NA
61 (12.0)
44 (7.0)
13 (4.4)
35 (18.4)
Private Payer
NA
NA
NA
NA
177 (34.7)
135 (21.4)
46 (15.7)
39 (20.5)
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Self-pay
Nocardiosis
disease form
Not specified
Cutaneous
Pulmonary
Disseminated
Neurologic
Costs/visit
(mean [SD])
Length of all
inpatient stays
(Mean days [std])

NA

NA

NA

NA

-

-

-

0

104 (8.4)
94 (7.6)
482 (38.9)
560 (45.2)
206 (16.6)

76 (8.2)
55 (5.9)
324 (34.8)
475 (51.1)
199 (21.4)

36 (6.6)
31 (5.7)
155 (28.6)
321 (59.1)
144 (26.5)

23 (5.1)
21 (4.6)
131 (28.9)
279 (61.5)
151 (33.2)

26 (5.1)
26 (5.1)
240 (47.1)
197 (38.6)
21 (4.1)

25 (4.0)
20 (3.2)
297 (47.0)
272 (43.0)
18 (2.9)

23 (7.8)
130 (44.2)
125 (42.5)
-

72 (37.9)
89 (46.8)
15 (7.9)

$2,160
($36,227)

$3,145
($43,181)

$3,214
($24,934)

$4,743
($74,200)

$29,837
($60,681)

$39,664
($189,242)

$35,702
($48,007)

$34,300
($29,576)

12.3 (16.5)

12.8 (13.6)

12.1 (11.6)

13.6 (15.8)

10.9 (13.1)

13.4 (15.9)

12.8 (13.7)

15.1 (15.4)

- = Suppressed counts when cell size <11
NA^ ESRD not assigned using ICD codes, so cannot be determined from HCUP data
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Table A.4: Pairwise Pearson correlation of continuous co-morbidity variables for nocardiosisassociated visits from the State Inpatient Databases (SID), n=1626
Variable
Chronic
Charlson
Nocardiosis
Mortality
conditions
Risk factors
score
Chronic
1.0
conditions
Charlson
0.398 <.0001 1.0
Nocardiosis
0.453 <.0001 0.389 <.0001
1.0
Risk factors
Mortality score
0.340 <.0001 0.417 <.0001
0.323 <.0001 1.0

3
4

Table A.5: Baseline demographic model estimating mortality and the model performance with
the addition of comorbidity measures
Baseline +
Baseline
Number of
Number of
Charlson
Model
Elixhauser
Nocardiosis
Chronic
Comorbidity
(Age,
Mortality Score
Risk
Conditions
Index
Sex*)
Factors
717.237
739.263
743.794
745.439
AIC^
757.200
C-statistic
0.608
0.718
0.669
0.654
0.641
HF-GOF±
0.357
0.1917
0.158
0.8337
0.97
OR
1.058
1.144
1.307
1.169
1.144,
1.040, 1.077
1.079, 1.214
1.080, 1.264
95% CI
1.494
*Sex was categorized into: 0-64, 65-75,75+ years old
^AIC= Akaike Information Criterion; intercept only model =763.931
±HF-GOF= Hosmer-Lemeshow Goodness of Fit test
Yellow cells indicate selected comorbidity measure

5
6
7
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